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A NOVEL ROLE FOR DYRK1A IN KIDNEY DEVELOPMENT
Alexandria Blackburn, B.S.
Advisory Professor: Rachel Miller, Ph.D.
Congenital anomalies of the kidney and urinary tract (CAKUT) are a leading cause
of pediatric kidney failure and encompass a wide range of structural malformations
resulting from defects in morphogenesis. CAKUT occur in ∼1/500 live births and with
an average wait time of 3-5 years for a kidney transplant, the need is high for the
development of new strategies aimed at reducing the incidence of CAKUT and
preserving renal function. Approximately 14% of CAKUT cases have a known
genetic component. This low causality suggests that CAKUT is complex and that
there are underlying genes and mechanisms which lead to CAKUT that have not
been identified. Next-generation sequencing has uncovered a significant number of
putative causal genes, including the novel observation that a cohort of patients with
DYRK1A haploinsufficiency has a higher prevalence of CAKUT (73% of those
assessed), including kidney defects. By using Xenopus laevis as a model we
determine that DYRK1A is essential for kidney development. Loss of dyrk1a in
Xenopus leads to abnormal kidney formation, which can be rescued. Furthermore, I
demonstrate that Dyrk1a perturbations lead to changes in β-catenin during
embryogenesis. This dissertation reveals a new gene important for kidney
development and disease and also has the potential to impact diagnostic patient
treatment strategies for DYRK1A-syndrome patients.
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CHAPTER 1: INTRODUCTION
This chapter is modified from Blackburn ATM, Miller RK. Modeling congenital kidney
diseases in Xenopus laevis. Dis Model Mech. 2019 Apr 9;12(4). pii: dmm038604.
doi: 10.1242/dmm.038604. https://dmm.biologists.org/content/12/4/dmm038604. Dis
Model Mech articles are published under a CC BY license, which establishes that
authors retain copyright in their articles.

1.1 Kidney Development
The kidney is an excretory organ that functions by reabsorbing nutrients and
excreting waste and excess fluid in the form of urine. Humans have two kidneys that
each drain through a separate tube called a ureter into the bladder. The structural
and functional unit of the kidney is the nephron. Each kidney contains around 1
million nephrons which are tubules that filter blood. Through this process, the
kidneys maintain salt, water, and pH homeostasis, as well as removing metabolic
waste byproducts (1). Additional functions of the kidney include regulating blood
pressure, converting vitamin D into its active form, stimulating red blood cell
production, and maintaining phosphate and calcium levels (2).
Anatomically, the kidney consists of three sections: the renal cortex, the renal
medulla and the renal pelvis. The renal cortex is the outermost part of kidney, while
the renal medulla is the innermost. All nephrons empty the blood ultrafiltrate through
their tubules into the collecting duct system which leads to the renal pelvis and then
drains into the ureter and bladder. There are two types of nephrons that exist. A
majority of nephrons (~85%) are cortical nephrons which have short loops of Henle
1

that just dip into the outer medulla (1). The remaining 15% are called juxtamedullary
nephrons. They have long loops of Henle that descend deeply into the medulla
which allow for the concentration of urine (1).
In humans, nephrogenesis starts at around 5 weeks of gestation and
completes between weeks 34-36 (3). Environmental factors such as vitamin A
deficiency or exposure to teratogenic substances can affect proper kidney
development (4, 5). Retinoic acid signaling is important for embryonic kidney
patterning and is derived from vitamin A, therefore deficits of it can lead to anomalies
(4). Additionally, taking angiotensin converting enzyme (ACE) inhibitors during
pregnancy can lead to congenital anomalies of the kidney and urinary tract
(CAKUT), as the kidney is essential in maintaining blood pressure through the reninangiotensin-aldosterone system (5).
The kidney is a unique organ in that it develops from successive forms that
replace the previous structure (Figure 1A-C) (6). These forms are the pronephros,
the mesonephros, and the metanephros. As each sequential form of the kidney is
superseded by the next, the organizational complexity increases (6). In mammals,
both the pro- and mesonephros are replaced by the metanephros, which persists as
the adult kidney (Figure 1) (2). It is important to note that although the pronephros is
non-functional in mammals, it is required for the subsequent formation of the
mesonephros and metanephros and the urogenital tract.
In mammals, the kidney arises from the intermediate mesoderm, which gives
rise to the nephric duct (Wolffian duct) and the metanephric mesenchyme (MM).
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Figure 1. Mammalian Kidney and Nephron Development.
The kidney develops from the intermediate mesoderm (labeled here as the nephrogenic
cord) in three successive forms, the pronephros, the mesonephros, and the metanephros,
which occurs in a cranial to caudal fashion. (A) In mammals the pronephros arises from the
nephrogenic cord and is a transient and non-functional structure which degenerates. (B)
Mesonephric nephrons are functional and develop more caudally from the nephrogenic cord
along the nephric duct/Wolffian duct but also degenerate. (C) The metanephric nephrons
form from the metanephric mesenchyme which condenses around the ureteric bud to form
(D) polarized renal vesicles. (E) A cleft in the renal vesicle leads to formation of the commashaped body. (F) An additional cleft leads to the formation of the S-shaped body, which (G)
elongates and fuses to the ureteric bud to form a mature metanephron that is patterned
along the proximal-distal axis where the proximal end becomes the podocytes and the distal
end becomes the distal tubule. The ureteric bud will become the complex arborized
collecting duct system which is induced from signals from the metanephric mesenchyme.
Although the pronephros is non-functional in mammals, it is required for the subsequent
formation of the mesonephros, metanephros, and the urogenital tract, which arises from or
along the nephric duct. (B-C) The cloaca is a temporary structure during embryogenesis.
3

The formation of nephrons and collecting ducts occurs through reciprocal
interactions between the MM and the ureteric bud (UB) (2, 7). The UB grows from
the nephric duct and will branch into a complex arborized network which gives rise to
the collecting duct system (7). This growth and branching is directed by signals from
the surrounding MM, which can be found around the branches of ureteric tips (2).
The MM is likewise induced by the UB to promote nephrogenesis which occurs at
the nephrogenic zone near the outer edge of the kidney (8). The cells closest to the
UB tips undergo epithelialization and form the renal vesicle (RV) which forms all
parts of the nephron (Figure 1D) (2). The RV forms a single cleft which creates the
comma-shaped body (Figure 1E), which is followed by another cleft to form the Sshaped body (Figure 1F) (2, 9). The S-shaped body is patterned along the proximaldistal axis where the proximal end becomes the podocytes and the distal end
becomes the distal tubule, with the proximal tubules and loop of Henle patterned in
between (2, 8).
An adult human kidney contains approximately one million nephrons (10)
whereas an adult mouse kidney has over ten thousand (11). Mammalian nephrons
develop asynchronously, making them challenging to study (12). In contrast,
Xenopus laevis, or frog embryos contain only one functional pronephric nephron on
either side of their body, which serves as the embryonic kidney (Figure 2). In
amphibians, the mesonephros serves as the adult kidney which replaces the
pronephros upon metamorphosis. Although the arrangement of kidneys differs, the
structural and functional unit of the kidney, the nephron, remains the same.
Therefore, the fully functional Xenopus laevis pronephric nephron serves as a
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Figure 2. The Xenopus Laevis Pronephric and Human Metanephric Nephrons Share
Conserved Tubule Segmentation Patterns Based on Gene Expression Data.
The schematic represents nephron segments, designated by different colors, in the
mammalian metanephric nephron (top) and the Xenopus laevis pronephric nephron
(bottom). The glomus/glomerulus filters blood across capillary walls into the proximal tubule,
which filters various wastes out of the body through the remaining distal and connecting
tubules. There are noted differences between the glomus and glomerulus in that the glomus
deposits blood filtrate into the coelomic cavity. Additionally, Xenopus laevis does not have a
loop of Henle (grayed out in human schematic) or a true collecting duct (grayed out in
human schematic), but instead has a region analogous to the connecting tubule closest to
the distal tubule of the mammalian metanephric nephron (13).

5

simplified model for mammalian meso- and metanephric nephron development
(Figure 2).

1.2 Conservation of the Nephron in Xenopus and Mammals
The pronephros forms from the intermediate mesoderm in both mammals and
amphibians. In Xenopus laevis embryos (hereafter referred to simply as Xenopus)
the nephric primordia is induced by signals from the surrounding tissues and forms
during neurula stages 12-15 (~16-20 hours post-fertilization), which will later
generate the tubules of the pronephros (14). Pronephros specification in Xenopus
occurs through interactions between the transcription factors Ors1/2, Pax8, Lhx1,
and Hnf1β, among others (15–18). Morphogenesis of the pronephros begins at the
early tailbud stage 21 (~23 hours post-fertilization)
(http://www.xenbase.org/anatomy/alldev.do).
In mice, the Ors1 gene is essential for the formation of renal structures and
can be found in the intermediate mesoderm, while Osr2 is found later on in the
mesonephros and is not essential (16). Consistent with Xenopus (19, 20), mice that
lack Lhx1 or Pax2/8 have severe kidney defects, though Pax2/8 seem to have
redundant functions in mice (21, 22). Finally, Hnf1β is expressed in the ureteric bud
as well as comma- and S-shaped bodies and mutations in this gene lead to kidney
cyst formation in mice (23). In addition, WNT (Wingless/Integrated), FGF (fibroblast
growth factor), BMP (bone morphogenetic protein) and GDNF (glial cell line-derived
neurotrophic factor) signaling pathways are involved in both Xenopus and
mammalian kidney development (9, 24).
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Analogous to the mammalian nephron, the amphibian pronephros is
segmented along its proximal-distal axis (25). Mammals have a glomerulus to filter
blood, proximal tubules for reabsorbing water and various nutrients, a loop of Henle
to concentrate urine, distal tubules for reabsorbing water and various nutrients, and
a collecting duct that reabsorbs water and carries urine from the kidneys to the
bladder (2). Similarly, Xenopus embryos have a glomus for filtering blood, proximal
and distal tubules for reabsorbing water and nutrients and a connecting tubule,
which opens out to the cloaca (Figure 2). In mice, the glomerulus forms at the most
proximal end of the S-shaped body which makes it linked to the development of the
rest of the nephron. Xenopus however, can develop a glomus independently from
the tubules, which may make understanding how the glomus forms more accessible
(26). In addition, at the tips of the proximal tubules, the amphibian also has multiciliated cells called nephrostomes, which cause fluid influx from the coelomic cavity
into the proximal tubules (27).
Each segment of the nephron has a specific function, which is reflected by
distinct cell morphologies (25) and gene expression signatures (13, 28). Strikingly
similar to mammals, the proximal tubules in Xenopus are responsible for
reabsorbing ions, water, glucose, and amino acids (13, 28–31). The most distal part
of the Xenopus proximal tubule is analogous to the mammalian proximal straight
tubule (13). Because Xenopus is an aquatic freshwater frog, it is unlikely that the
amphibian pronephros requires a true loop of Henle for concentrating urine. Within
the literature, the Xenopus intermediate tubules have been defined using markers
that are co-expressed in the proximal and distal tubules of the mouse kidney (13,
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32). Thus, assessment of a marker that is exclusive to this region is necessary to
confirm or refute the existence of this structure and will be called early distal in this
dissertation. The Xenopus distal tubule is analogous to the thick ascending limb of
the loop of Henle and the distal convoluted tubule in mammals (13), and it functions
to transport ammonium, reabsorb magnesium ions and is important for urine
acidification (13, 28, 33, 34). The pronephric connecting tubule of Xenopus connects
the distal tubules to the cloaca to excrete urine and is only analogous to mammals in
the region neighboring the distal tubule (13). The pronephros does not have a
collecting duct to further concentrate urine or connect multiple nephrons to a
secondary structure, as is necessary for the mammalian metanephros.
Recently, it has been shown that human and mouse nephron protein
expression signatures in the renal vesicles and S-shaped bodies are very similar
(35). Not surprisingly, Xenopus shares similar gene expression signatures during
early pronephric development in the kidney (Figure 3). Although this figure only
illustrates four gene expression signatures, it is important to note that of the 29
expression signatures identified in the human embryonic kidney (35),18 can also be
found in the Xenopus kidney (Xenbase.org). Additionally, a comparison of gross
expression signatures in the kidney demonstrated similarities between mouse and
Xenopus in both overlapping transcription factors such as Pax8 and additional ones
such as Foxc1 and Sall1 (36). Furthermore, some of the proteins analyzed in
humans have not been studied in Xenopus, potentially leading to an underestimate
of the similarities. This overall conservation on the molecular, genetic, structural, and
functional levels supports the use of the Xenopus pronephros as an appropriate
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Figure 3. Expression Patterns are Conserved Between the Human S-shaped Body and
the Early Xenopus Pronephros During Development.
Four different expression patterns (shown in different colors) of fundamental kidney
proteins/mRNA were chosen to demonstrate the similarities between the developing human
and Xenopus nephron. Schematics indicate where immunostaining of S-shaped body
nephrons of week 16 to 17 human fetal kidneys is present (top) (35), as well as in situ
expression patterns of stage 33 Xenopus nephrons (bottom) (Xenbase.org). Schematics are
positioned so that the proximal and distal regions of the human and Xenopus nephron
expression patterns can be easily compared. The Xenopus kidney stage was chosen to
match the approximate developmental time point of human S-shaped body nephrons, as
both are representative of recently epithelialized nephrons. Note that pax2 is slightly more
enriched at the nephrostomes in Xenopus (dark green).
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model for the study of congenital kidney anomalies.

1.3 Wnt Signaling in Kidney Development
The Wnt signal transduction pathway is an evolutionarily conserved pathway
where Wnt glycoproteins are secreted to nearby cells. Wnt signaling has been
implicated in embryonic organogenesis, fate determination, cell polarity, cell
migration, and neural patterning (37). There are three major pathways for Wnt
signaling: canonical/β-catenin, non-canonical planer cell polarity, and the noncanonical calcium pathway (Figure 4). The upstream event of all pathways is the
same: Wnt ligands are secreted from one cell and bind the extra-cellular domain of a
Frizzled (FZD) receptor of a neighboring cell which is than transduced to the
neighboring cell’s interior to the phosphoprotein Dishevelled (DVL) (37–39). After
that, to activate the planar cell polarity (PCP) pathway, either Dishevelled-associated
activator of morphogenesis 1 (DAAM1) or Rac are recruited to modulate actin
polymerization to alter the cytoskeleton (Figure 4B) (37). The Wnt/calcium pathway
recruits a trimeric G-protein which leads to PLC activation and calcium release
(Figure 4C) (37). In canonical Wnt signaling, in the absence of a Wnt ligand, the
cytoplasmic protein β-catenin is targeted for degradation by the destruction complex.
The destruction complex is composed of Axin, adenomatous polyposis coli (APC),
casein kinase 1α (CK1α), and glycogen synthase kinase 3 (GSK3) (Figure 4A) (37,
39). While in this complex, CK1α and GSK3 phosphorylate β-catenin which targets it
for ubiquitination and proteasomal degradation. However, in the presence
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Figure 4. Wnt Signaling Pathways.
There are three major pathways for Wnt signaling: canonical/β-catenin, non-canonical
planer cell polarity, and the non-canonical calcium pathway. The upstream event of all
pathways is the same: Wnt ligands are secreted from one cell and bind the extra-cellular
domain of a Frizzled (FZD) receptor of a neighboring cell which is than transduced to the
neighboring cell’s interior to the phosphoprotein Dishevelled (DVL) (37–39). (A) In the
absence of a Wnt ligand, the destruction complex (Axin/APC/CK1/GSK3β) targets β-catenin
for proteasomal degradation (OFF). When a Wnt ligand binds, LRP5/6 binds to a FZD
receptor which inhibits the destruction complex from phosphorylating β-catenin. β-catenin is
then able to translocate to the nucleus and bind TCF/LEF1 which leads to activation of
canonical Wnt target genes. (B) To activate the planar cell polarity (PCP) pathway, either
DAAM1 or Rac are recruited. DAAM1 activates RhoA which activates Rho-associated
kinases (ROCK) and leads to cytoskeletal rearrangements. Alternatively, Rac or RhoA lead
to c-Jun n-terminal kinase (JNK) which controls cell polarity and movement (40). (C) The
Wnt/calcium pathway requires Wnt ligand to bind leading to FZD receptor interaction coreceptor retinoid-related orphan receptor/ receptor like tyrosine kinase (ROR/RYK) leading
to recruitment of a trimeric G-protein. This leads to phospholipase C (PLC) activation which
can activate diacylglycerol (DAG) through protein kinase C (PKC) to stimulate cell division
control protein 42 (CDC42) mediated cell movements (37). Additionally, PLC activation can
lead to inositol trisphosphate (IP3) activation which releases intracellular calcium to activate
Calmodulin. Activation of Calmodulin causes transforming growth factor beta-activated
kinase 1 (TAK1) to activate nemo like kinase (NLK) which inhibits β-catenin/TEF function.
Alternatively, Calmodulin can lead to calcineurin (CaN) and NFAT activation (37).
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of a Wnt ligand, the destruction complex is disassembled, leading to β-catenin
stabilization. This stabilization allows β-catenin to translocate to the nucleus and
bind to transcription factor T-cell factor/lymphoid enhancer factor (TCF/LEF) to
activate Wnt target genes (37). This occurs when FZD binds to the low density
lipoprotein receptor related protein (LRP5/6), recruiting DVL which leads to
phosphorylation of LRP5/6 which in turn recruits Axin and disrupts the destruction
complex (39).
The canonical Wnt/β-catenin pathway has been identified as a key regulator
in kidney development in both mammals (41, 42) and Xenopus (43, 44). Wnt
signaling is necessary for nephron induction in mice (45) and is essential for renal
branching morphogenesis (46), as well as maintaining the nephron progenitor pool
(47). In humans, loss-of-function mutations in canonical Wnt ligand WNT4 have
been associated with renal hypodysplasia, a condition characterized by dysplastic
kidneys with a reduced number of nephrons (48). Studies in Xenopus demonstrate
that Wnt4 protein controls the medio-lateral patterning of the pronephros (49).
Additionally, knockdown of Wnt4 protein in Xenopus results in complete loss of
kidney tubules (43).
In addition to Wnt ligands, other proteins have been found to regulate Wnt
signaling. In humans, Wilms Tumor 1 (WT1) is a known regulator of canonical Wnt
signaling. Mutations that affect WT1 result in nephroblastoma, more commonly
known as Wilms tumor (50). Knockdown of Wt1 protein expression was shown to
reduce Wnt4 expression in the prospective pronephros of Xenopus embryos (51).
Both overexpression or loss of canonical Wnt signaling in Xenopus leads to loss of
13

kidney tubules whereas overexpression of β-catenin in the mouse kidney leads to
severe polycystic lesions that affect the entire nephron (52). These studies in both
Xenopus and mouse models demonstrate that too much or too little Wnt signaling
results in kidney abnormalities, suggesting that endogenous levels must be tightly
maintained to achieve proper nephrogenesis.

1.4 Modeling CAKUT in Xenopus
CAKUT are a leading cause of pediatric kidney failure, accounting for 40–
50% of pediatric chronic kidney disease (CKD) worldwide (53). CAKUT
encompasses a wide range of structural malformations resulting from morphogenetic
defects, including Wilms tumor and renal hypodysplasia (Figure 5) (54). With an
average five-year wait time for a deceased donor kidney transplant (United Network
for the Organ Sharing), the need to find alternative treatments that preserve renal
function is essential. Monogenic disease with strong genetic causality only accounts
for 14% of CAKUT (55), and polygenic causes are speculated to occur but are
largely unknown (56). Next-generation sequencing has helped to uncover novel
causative genes of CAKUT, but a high-throughput strategy to test their function in
the kidney is needed. To understand how CAKUT arises, it is crucial to understand
how the kidneys and urinary tract develop to uncover the genetic mechanisms that
coordinate these events. Mice and zebrafish have been the predominant models
used in kidney research, while recent advances have made kidney organoids useful
for nephrotoxicity screening as well as modeling kidney diseases (57). However,
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Figure 5. Common Malformations of the Kidney Found in CAKUT.
Renal malformations resulting from inherited kidney diseases are depicted in colored boxes.
The colors correspond to the color coding for genes whose loss results in the given
phenotype. (1) Green represents renal cysts that are large and cover the majority of the
kidney, as seen in renal dysplasia, multicystic dysplastic kidney (MCDK) and autosomaldominant polycystic kidney disease (ADPKD). (2) Magenta represents a tumor, as seen in
tuberous sclerosis and Wilms tumor. (3) Purple represents kidney agenesis. (4) Teal
represents renal hypoplasia, which is one of the most common CAKUT phenotypes. (5)
Orange represents nephronophthisis, with maroon spots depicting corticomedullary cysts,
which are generally small. (6) Blue represents horseshoe kidney, where both kidneys are
fused together. (7) Red represents ureter malformations and blockages, which result in urine
backflow into the kidney (shown in yellow in the schematic). Genes listed in the key have
been studied or are expressed in the Xenopus kidney. Colored boxes and numbers that
correspond to the aforementioned phenotypes can also be found in Table 1 under ‘Renal
phenotype’

16

Xenopus possesses many qualities that make it an effective in vivo model to study
congenital kidney diseases.
Xenopus share a relatively close evolutionary history with mammals because
they are tetrapods. Thus, this model has the advantage of rapid development, like
zebrafish, but evolutionarily, it lies closer to mammals. Additionally, Xenopus and
human genomes have long stretches of gene colinearity and 79% of identified
human disease genes have a verified ortholog in Xenopus (58). The embryonic
kidney of Xenopus has many characteristic features of a mature mammalian kidney
(Figure 2) (13, 28). Thus, many genes and processes necessary for Xenopus kidney
development are also important in mammalian kidney development. Furthermore, a
number of kidney disease-causing genes have been analyzed in Xenopus or are
expressed in its embryonic kidney, introducing potential paths for future kidney
research (Figure 5 and Table 1). Though relatively few in number, the Xenopus
genes studied have been shown to function in kidney development as their
mammalian orthologs do in mammalian kidneys, and they result in similar nephron
phenotypes when their expression is disrupted. Additionally, Xenopus possesses
unique qualities that other in vivo model systems lack.
With a simple hormone injection, Xenopus produces large clutch sizes with
hundreds of embryos that develop externally. Their kidneys can easily be visualized
and imaged through their transparent epidermis, and they develop a fully functional
kidney in ~56 hours (15). Additionally, cleavage-stage Xenopus embryos have been
fate-mapped, which allows for the tracking of specific blastomeres as they develop
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Gene
Symbol

Renal
Phenotype

Human disease

Contribution of
Xenopus

Mode of
inheritan
ce

References

ACE

renal
dysgenesis

Renal tubular
dysgenesis

ACE activity detected at
high levels in kidney and
testes

recessive

(59, 60)

AGT

renal
dysgenesis

Renal tubular
dysgenesis

Mitochondrial targeting
in liver cells

recessive

(60, 61)

ANKS6
(NPHP16)

Renal cysts5,
renal
hypoplasia4

Nephronophthisis,
situs inversus

Role in early tubule
morphogenesis

recessive

(62, 63)

BICC1

Renal cysts,
renal dysplasia1

Renal disease

Regulates renal
epithelial cell
differentiation, defects in
left-right patterning

N/A

(64–67)

BMP4

Renal
hypodysplasia4

Microphthalmia,
syndromic 6
Orofacial cleft 11

Important for ventral
mesoderm formation,
BMP signaling mediates
pronephric tubule and
duct formation

dominant

(68–70)

BMP7

UVJ
obstruction7,
hypodysplasia4

CAKUT

Expressed in
pronephros

dominant

(71, 72)

CLCNKB

Hypochloremia,
proteinuria

Bartter Syndrome
type III

Important for chloride
conductance

recessive

(33, 73, 74)

EYA1

Renal
hypodysplasia4

Branchio-oto-renal
syndrome

Important for normal ear
development, not
analyzed in pronephros

dominant

(75, 76)

FOXC1

Renal
hypoplasia4

CAKUT, AxenfieldRieger Syndrome

Expression in
pronephros

dominant

(77, 78)

FOXC2

Hydronephrosis
, horseshoe
kidney6,
proteinuria,
renal cysts1

Lymphedemadistichiasis
syndrome with
kidney disease and
diabetes mellitus

Required for podocyte
gene expression

dominant

(79, 80)

GATA3

Renal
dysplasia1

HDR Syndrome

Expressed in pronephric
duct.

dominant

(81, 82)

GDNF

Kidney
agenesis3,
renal
dysgenesis,
nephrotic
syndrome

CAKUT,
Hirschsprung
Disease

Expressed in
pronephros

N/A

(83, 84)

HNF1β

Renal
hypodysplasia4,
sporadic renal
dysplasia, renal
cysts1, renal
agenesis3,
horseshoe
kidney6

MODY5, Renal
cysts and diabetes
syndrome

Distinct renal
phenotypes based on
specific human
mutations

dominant

(23, 85–89)

INVS
(NPHP2)

Renal cysts5,
tubular lesions

Nephronophthisis,
situs inversus

Role in early tubule
morphogenesis

het and
homo

(62, 90)

LHX1/XLI
M1

MCDK1

CAKUT

Important for proper
renal development

N/A

(20, 87)
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LMX1β

Renal cysts1,
microscopic
haematuria,
proteinuria

Nail-patella
syndrome, nephrotic
syndrome, nailpatella-like renal
disease

Critical for glomus
development, Found its
position in gene
regulatory network of
podocyte specification

dominant

(80, 91–93)

NEK8
(NPHP9)

Renal cysts5

Nephronophthisis,
Meckel–Gruber
syndrome

Role in early tubule
morphogenesis

recessive

(62, 94)

NPHP3

Renal cysts5,
tubular lesions

Nephronophthisis,
situs inversus,
Meckel–Gruber
syndrome, RenalHepatic-Pancreatic
Dysplasia

Role in early tubule
morphogenesis

het and
homo

(62, 95)

NRIP1

Renal
hypo/dysplasia4
, VUR7

CAKUT

Important for proper
renal development

dominant

(96)

PAX2

Renal
hypoplasia4,
VUR7, Renalcoloboma
syndrome

Pallilorenal
syndrome

Essential for tubule
differentiation

dominant

(19, 97)

PKD1

Renal cysts1

ADPKD type 1

Expressed in
pronephros

dominant

PKD2

Renal cysts1

ADPKD type 2

Post-transcriptionally
positively regulated by
BicC via repression of
miR-17

dominant

(65, 100, 101)

RET

Renal
agenesis3

CAKUT,
Hirschsprung
disease

Expressed in pronephric
duct

dominant

(102, 103)

SALL1

Renal
hypodysplasia4,
MCDK1, PUV,
UPJ
obstruction,
VUR7

CAKUT, TownesBrocks syndrome

Expressed in
pronephros

dominant

(72, 104)

SIX1

Renal
hypodysplasia4

Branchio-oto-renal
syndrome

Potential six1 gene
targets expressed in
kidney

SIX2

Renal
hypodysplasia4

CAKUT

Conserved enhancers
regulate pronephros
specific expression

dominant

(69, 107)

SOX17

VUR, UPJ
obstruction7

CAKUT

Important for endoderm
formation

dominant

(108, 109)

TSC1

Kidney tumors2

Tuberous sclerosis

Down regulated by
miRNAs to control
proximal tubule size

dominant

(110)

WDPCP
(FRITZ)

Renal
malformation,
genital
abnormalities

Bardet-Biedel
syndrome

Controls septin
localization at cilia,
linked mutations in
human wdpcp to BardetBiedl and MeckelGruber syndromes

recessive

(111, 112)

WNT4

Renal
hypodysplasia4

Mullerian aplasia
and
hyperabdrigenism,
SERKAL syndrome

Patterns the proximal
pronephric primordia,
Regulated by notch, wt1
and sox11

dominant

(42, 43, 48, 49, 51)

dominant

(67, 98, 99)

(105, 106)
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WT1

Kidney tumors2

Wilms-tumor type 1,
Denys-Drash
syndrome, Frasier
syndrome,
Nephrotic syndrome
type 4

Key regulator of glomus
development, Regulates
wnt4 expression in the
pronephros

dominant

(50, 51, 80)

Table 1. CAKUT Genes That Have Been Analyzed or Have Kidney Expression in
Xenopus.
Colors and superscripts 1-7 correspond to the numbers found in Figure 5 (1, green; 2,
magenta; 3, purple; 4, teal; 5, orange; 6, blue; 7, red). Underlined indicates studies were
performed in Xenopus to validate that specific mutations cause human kidney phenotypes.
CAKUT, congenital anomalies of the kidney and urinary tract; Het, heterozygous; Homo,
homozygous; MCDK, multicystic dysplastic kidney; PUV, posterior urethral valves; UPJ,
ureteropelvic junction obstruction; UVJ, ureterovesical junction obstruction; VUR,
vesicoureteral reflux.
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from an early stage embryo into a differentiated body plan (113, 114).This facilitates
unilateral tissue-targeted injections that are specific to organs such as the kidney
(115) and permits using the uninjected side as an internal control. In addition,
researchers have developed assays to study kidney function in Xenopus.
Xenopus oocytes and early embryos can easily be injected with DNA, mRNA,
protein, and/or morpholinos (MO) to overexpress or knock down proteins. A common
assay in Xenopus involves disrupting genes/proteins in both kidneys by injecting
MOs or CRISPR sgRNAs and Cas9 protein in both ventral cells of four-cell embryos.
If the gene/protein is important for kidney formation, its loss will result in edema,
characterized by swelling in the chest cavity due to fluid retention. This technique
allows for disruption of the kidney while avoiding the heart and liver (xenbase.org),
two other common causes of edema, generating tissue-targeted knockdown or
knockout embryos. Upon edema formation researchers can then use an excretion
assay, allowing visualization of the passage of fluorescent molecules through the
kidney and out through the cloaca which can show if the kidneys are still functioning
(28). Though not directly comparable to the Cre/loxP systems used in mouse
studies, this edema assay, which is unique to Xenopus, allows for some evaluation
of tissue specificity.
Knockdown of Pkd2, a protein involved in autosomal dominant polycystic
kidney disease (ADPKD), in Xenopus embryonic kidneys results in edema (65).
Similar edema phenotypes occur due to the loss of other proteins implicated in
CAKUT such as Pax2 and Pax8 (19). These established techniques demonstrate
that Xenopus possesses distinctive qualities suitable for disease modeling, and new
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technologies continue to improve the experimental opportunities in this model
system.
Genetic screens of the allotetraploid Xenopus are becoming more feasible
with the development of the CRISPR/Cas9 system (116) and the ability to target
CRISPR-mediated genetic manipulation to the kidney is unique to Xenopus (20).
Additionally, inducible systems such as Gal4-UAS (117), Tet-On (118), heat-shock
inducible (86, 89), and the Dex-inducible strategy (119) have been successfully used
in Xenopus embryos, which allows for temporal or spatial control of gene
expression. These tools make Xenopus a valuable model for studying the kidney,
can aid in our understanding of the mechanisms through which the kidney develops,
and can help identify new genes important for renal function.

1.5 Delineating Molecular Pathways Involved in Kidney Development Using
Xenopus
Xenopus has been historically used to elucidate molecular mechanisms and
signaling cascades involved in early developmental processes (120). More recently,
Xenopus has been used to model various human genetic diseases (121).
Importantly, Xenopus has played a vital role in identifying the function of genes that
are involved in CAKUT.
Mutations in the RNA-binding protein BICC1, a negative Wnt regulator, result
in a cystic kidney phenotype in mice and renal anomalies in patients (66). Prior
studies in Xenopus indicate that Bicc1 inhibits the microRNA miR-17, preventing
miR-17 from destabilizing the pkd2 transcript (65). This was demonstrated by
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showing a rescue of the kidney phenotype when both miR-17 and Bicc1 were
knocked down in tadpoles simultaneously (65). Interestingly, loss of the Pkd1 gene
product, polycystin-1, downregulates BICC1 expression in mouse kidneys and
mouse cell lines (67). The connection between BICC1 downregulation and
polycystin-1 loss in mice and Bicc1 stabilizing pkd2 mRNA in Xenopus suggests that
disruption of BICC1 may induce cystic phenotypes through polycystin signaling.
Similarly, targeted deletion of Hnf1β, a key transcription factor involved in kidney
development, decreases Bicc1 and Pkd2 mRNA expression in the mouse kidney
(88). HNF1β in the mouse (88, 122) and BICC1 in mice and Xenopus (65) regulate
the Pkd2 transcript, and mutations in either gene can lead to kidney cysts in mouse
models (23, 65). Thus, it is likely that these genes act through the same or similar
pathways. Xenopus would be an ideal model for looking at the components of this
pathway because molecular strategies to assess these components have already
been established (64, 65).
Another common congenital kidney disease whose pathway has been
elucidated using Xenopus is Nephronophthisis (NPHP). NPHP is a ciliopathy, which
results in either abnormal formation or function of cilia. NPHP is a rare birth defect,
but it is the most common cause of kidney failure, or end-stage renal disease
(ESRD), in the first three decades of life (123). Studies in Xenopus linked several
genes with NPHP or clarified components of the mechanism that causes the
disease. First, targeted kidney knockdown of the Wnt signaling inhibitor Invs
(Inversin/NPHP2) demonstrated that Inversin is important for morphogenetic cell
movements during tubule elongation (124).This knockdown led to impaired ventral
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proximal pronephros extension and distal tubule differentiation (124). Later, it was
discovered that several genes that cause NPHP form a distinct complex that
contributes to kidney development. In Xenopus, Anks6 was identified as an NPHP
family member which assembles a protein complex of the NPHP-associated proteins
Nek8, Inversin, and Nphp3 to regulate kidney development (62). This study showed
that Anks6 localizes to the base of the cilium and that knockdown of its protein
expression results in kidney anomalies (62). The study also linked ANKS6 mutations
in patients with a nephronophthisis-like clinical syndrome (62). Additionally,
knockdown of either Anks6 or Nphp3 protein in Xenopus embryos results in edema,
which suggests they may be important for kidney function (62). Likewise, edema in
Xenopus has been shown to occur due to depletion of Invs protein (124).
Although Xenopus has helped uncover some of the causative NPHP genes
and their role in kidney development and function, only ~40% of patients have a
mutation in one of the 20 known NPHP-related genes (125, 126). A recent GenomeWide Association Study has uncovered epigenetic signatures of chronic kidney
disease including NPHP4 (127). Some NPHP patients may suffer from epigenetic
alterations of NPHP genes rather than a mutation in the gene itself. Future research
using Xenopus may lead to the identification of new NPHP-causing genes and may
uncover further epigenetic regulation of known genes as amphibians have been
used to study epigenetics.
A notable CAKUT-causing gene encodes the transcription factor LMX1β,
where mutations can lead to Nail-patella syndrome, a rare cause of autosomal
dominant ESRD (93). Additionally, mutations in LMX1β can result in
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glomerulopathies. Mouse studies suggest that Lmx1β is necessary for the
maintenance of podocytes, which are highly specialized cells that wrap around
capillaries of the glomerulus and restrict the passing of macromolecules into the
kidney (91). In Xenopus, lmx1β is expressed in the glomus, which is analogous to
the mammalian glomerulus, and is also known to have a role in podocyte
specification (80, 92). MO knockdown of Lmx1β protein in Xenopus showed that the
glomus was reduced in size, and the development of the proximal tubules was
reduced (92). Taken together, these studies demonstrate the usefulness of Xenopus
in uncovering the role of proteins important for kidney development and function.
Additionally, they show that Xenopus is capable of recapitulating specific kidney
disease phenotypes found in humans.

1.6 Using Xenopus to Examine Human Genetic Variants
In human studies, missense mutations are often analyzed via software
programs such as PredictSNP (128) and Meta-SNP (129). These programs predict
the functional relevance of an amino acid change and suggest if they are likely to be
pathogenic. One drawback of this method is the surprising data from 1000 Genomes
indicating that people with predicted pathogenic variants do not suffer from the
expected disease (130). Xenopus can be used to verify the pathogenicity and
expressivity of potential disease-causing genetic variants in vivo.
Work in mouse models found that the ion channel protein CLCNKB is
important for concentrating urine (131). In humans, CLCNKB mutations cause a saltlosing tubulopathy known as Bartter syndrome type III (73). Because Xenopus
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oocytes are equipped with all of the necessary machinery for development upon
fertilization they have been used broadly to study channel proteins. In fact, the first
genotype/phenotype correlation for Bartter syndrome type III was validated by
functional analyses of eight missense and two nonsense mutations in Xenopus. By
performing voltage clamp experiments in Xenopus oocytes, it was found that nine of
the ten mutations significantly decreased normal conductance (74), indicating
altered salt homeostasis. This work verified that the reported human genetic
mutations were, in fact, Bartter syndrome type III-causing mutations (74). Given the
large number of ion channels present in the kidney, this system can be readily
exploited to study patient mutations in various channels and their effects on
conductance.
A similar study demonstrated that dysregulation of NRIP1-dependent retinoic
acid signaling in both Xenopus and mouse disrupted kidney formation (96). In
Xenopus, knockdown of Nrip1 protein causes kidney anomalies that can be rescued
with wild-type human NRIP1 mRNA but not with the truncated NRIP1 mRNA
identified in patients (96). Xenopus can also serve to assess the distinct effects of
different mutations in a single gene.
HNF1β mutations have been shown to manifest as distinct renal diseases in
humans (85). An attempt to model these differences in Xenopus was successfully
executed using different methods in two separate studies. In the first study, Xenopus
transgenic lines expressing two different human HNF1β mutants using a heat shockinducible Cre/loxP system were generated. One transgenic line expressed an
insertion mutation, while the other line expressed a deletion mutation. The deletion
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led to reduced pronephric development, while the insertion enlarged the pronephros,
with both phenotypes primarily affecting the proximal tubules (89). The second study
compared nine different human HNF1β mutations including indels
(insertions/deletions), missense, and nonsense mutations by injecting mutant
mRNA. The mutations led to distinct renal disease phenotypes in Xenopus, as they
do in humans (85). In Xenopus, six of the mutants resulted in an enlargement of the
pronephric structures, while the other three mutations led to a reduction or loss of
the tubules and the anterior part of the duct (85). Additionally, a new transgenic line
has the potential to make modeling human variants easier.
The cdh17:eGFP frog line has recently been developed in which GFP is
expressed in the epithelium of the pronephros and mesonephros (132). This permits
live imaging of the developing kidney, which can also be used to assess kidney
disruption upon specific gene knock down/out without the need for immunostaining
or in situ hybridization. This Xenopus line has the potential to streamline large-scale
screens of kidney disease-causing genes and environmental factors that affect renal
development. Also, bypassing the need to process embryos will expedite drug
discovery screening in Xenopus (133), that may ultimately lead to clinical
applications.
The above data demonstrate that the range of kidney phenotypes seen in
Xenopus recapitulate the kidney phenotypes observed in humans. This potentially
allows for a correlation between an observed patient phenotype with a specific
mutation in the HNF1β gene. Studies like these are an efficient way to identify
pathogenic genetic variants and can represent the variation of expressivity seen in
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patients. Additional variants found in the DYRK1A human gene have been examined
using Xenopus and will be further discussed in Chapter 3.

1.7 DYRK1A
The dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) family
is composed of DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4 (134) and they
phosphorylate their substrates at serine or threonine residues. DYRKs belong to the
CMGC group of kinases, which includes cyclin-dependent kinases (CDKs), mitogenactivated protein kinases (MAPKs), glycogen synthase kinase-3 (GSK3), CDK-like
kinases, serine/arginine-rich protein kinases, cdc2-like kinases, and RCK kinases
(135). Most protein kinases function as molecular switches that require an upstream
kinase to adopt an active conformation. The DYRK family is unique in that they do
not require an upstream event, but rather they autophosphorylate on a tyrosine
residue in their activation loop (135, 136), which earned them their name “dualspecific”. This autophosphorylation event allows them to maintain an active
conformation, which makes DYRK’s extremely dose dependent. Another
commonality to the DYRKs is that they contain a DYRK homology (DH) box just Nterminal to the kinase domain (135). Both DYRK1A and DYRK1B contain additional
homology by having nuclear localization signals (NLS) and a PEST motif (135).
DYRK1A is the only member that contains a histidine repeat motif and a
serine/threonine–rich motif (135). Of all the DYRK family members, DYRK1A is the
most well-studied (137).
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DYRK1A is highly evolutionarily conserved and has been implicated in cell
survival, differentiation, and neurogenesis (136, 138). DYRK1A has a different
consensus sequence (RPXS/TP) (139) than DYRK2/3 (RXS/TP) (140) which gives
them differences in the substrates that they phosphorylate (140). DYRK1A was first
described in the literature in 1986, in Drosophila as minibrain, where it lead to a
smaller brain size in flies (141). The mammalian homolog was not studied until
almost a decade later (142) and shortly after that it was found to be a candidate
gene for intellectual disability in Down syndrome because of its chromosomal
location within the “Down syndrome critical region” (21q22.2) and its neurogenic
defects in Drosophila (141, 143). Further studies have indicated that DYRK1A
overexpression in Down syndrome is causative for intellectual disability (138, 144).
Similarly, haploinsufficiency of DYRK1A causes intellectual disability, developmental
delay, microcephaly, dysmorphic facial features, and seizures (145). Collectively,
DYRK1A haploinsufficiency is known as DYRK1A-related intellectual disability
syndrome (DYRK1A syndrome). Because DYRK1A is always catalytically active and
loss or gain of a DYRK1A allele has severe phenotypic consequences, it is believed
that DYRK1A may be controlled by subtle changes (146). There are several ways
DYRK1A is transcriptionally regulated. It was found that Activator protein 4 is a
transcriptional repressor of DYRK1A in non-neural cells. Also, the transcription factor
E2F1 was shown to positively regulate DYRK1A by promoting enhancer activity
(146, 147). Additionally, NFATc1 was found to upregulate DYRK1A in bone marrow
macrophages which serves as a negative feedback loop given that DYRK1A
maintains inactive NFAT (146). Furthermore, DYRK1A’s PEST motif suggests that it
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may undergo rapid protein turnover, as PEST motifs are thought to act as a
degradation tag for proteasomal destruction. One study demonstrated that in
HEK293 cells DYRK1A has a half-life of 14 hours and that a conserved region in its
N-terminus, not its PEST domain, was responsible for βTrCP-meditated degradation
(147). Given that DYRK1A promotes cell cycle exit and therefore inhibits
proliferation, dysregulation of DYRK1A may play a role in different disease states
(147).
Because of its neurological implications DYRK1A has been heavily studied in
the brain. There, it has been found to play a role in many different signaling
pathways including calcium signaling, Sonic Hedgehog signaling, and canonical Wnt
signaling (148–150). It also has been found to inhibit of N-WASP in vitro and in the
rat hippocampus which may disrupt cell migration by inhibiting filopodia formation
(151). Due to DYRK1A’s association with multiple neurological defects, it has only
been studied in a handful of other tissues. But phenotypic clues from DYRK1A loss
have lead us to look into the urogenital system. Whole exome sequencing has
identified a cohort of 19 patients with DYRK1A syndrome that have increased
prevalence of urogenital abnormalities (~73%) including renal agenesis and
hypospadias. This prompted the start of my dissertation research: to understand if
DYRK1A was the cause of this increased prevalence of CAKUT.

1.8 Approaches to Discover Novel CAKUT Genes
Monogenic disease only accounts for 14% of CAKUT cases (55). Genetic
diagnosis of CAKUT is complicated by having genetic and phenotypic heterogeneity,
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variable penetrance, and a high level of sporadic cases (53). A potential reason for
the variability seen among patients with mutations in the same gene is dosage.
Different mutations, such as those that affect DNA binding, could lead to a difference
in protein expression of that gene during kidney development which could ultimately
lead to phenotypic variability.
In the age of omics, exome-sequencing has identified many potential genes
involved in CAKUT. An additional approach is through genome-wide analysis. In a
recent study, genome-wide analysis of almost 3000 CAKUT patients identified 45
different genomic disorder-associated copy number variations (GD-CNV) at 37 loci
(152). Interestingly, 6 of the loci were found in 65% of CAKUT patients, which are
likely to code for regulators of urogenital development (152). Potentially, even more
edifying is that specific urogenital anomalies and kidney malformations were
associated with specific types of genomic changes. For instance, patients with
vesicoureteral reflex and posterior urethral valves mostly had genomic duplications,
whereas obstructive uropathies had mostly deletions, and horseshoe kidney and
lower urinary tract malformations such as bladder anomalies were not associated
with either (152). This could indicate that efforts in searching for vesicoureteral reflex
pathologies should be spent looking for genes that are sensitive to gene dosage,
whereas those looking for lower urinary tract malformations should focus on
individual genetic mutations. This method can also identify non-coding sequences
that may be important regulatory elements involved in kidney development (153).
Additionally, this type of analysis may be able to identify specific pathways or genes
that are involved with specific renal outcomes. For instance, a specific CNV may
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mainly cause obstructive uropathies and a specific receptor or ligand was found
within the CNV which could implicate a new pathway in ureter formation.
Because monogenic disease accounts for a fraction of CAKUT cases,
epigenetic alterations are likely to play a role. Epigenetic alterations can be tested
through assays such as ChIP-sequencing. One study compared samples of nephron
tubules in healthy patients to those of patients with chronic kidney disease. They
showed methylated regions that were different between the two groups overlapped
with enhancer regions and contained binding motifs for transcription factors such as
SIX2, which is essential for kidney development (154). Epigenetic alterations are
reversible, but they are also sensitive to environmental factors.
There are several in utero environmental factors that are risk factors for
developing CAKUT including maternal diabetes mellitus and maternal
overweight/obesity (154). Additional environmental risk factors include fetal
exposure to alcohol, tobacco, vitamin A deficiency, and maternal medication
exposures such as ACE inhibitors and glucocorticoids (155–157). These
environmental risk factors can lead to changes in epigenetic marks that may repress
or activate genes during different stages of renal development which can lead to
CAKUT.
Given the toolbox we now have to find novel CAKUT genes, more are likely to
be implicated in pathogenesis in the future. Epigenetic analysis can elucidate our
understanding of how important regulators of kidney genes are controlled during
nephrogenesis. This type of dysregulation could ultimately affect the structure of the
kidneys, ureter, nephrons or even the total nephron count. It would not be surprising
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to find that dysregulation of gene dosage by epigenetic or environmental factors
rather than genetic mutations may play a significant role in maintaining proper
urogenital development.

1.9 Dissertation Summary
Congenital anomalies of the kidney and urinary tract account for 40–50% of
pediatric chronic kidney disease worldwide. Although important advances have been
made in basic nephrology research, there are still missing pieces in the molecular
basis of kidney organogenesis. Being able to uncover novel genes and pathways
involved will give us a better understanding of kidney development as a whole. Nextgeneration sequencing has uncovered many putative causal genes, including
DYRK1A. A cohort of patients with DYRK1A intellectual disability syndrome which
results from haploinsufficiency has a higher prevalence of CAKUT (73% of those
assessed), including kidney defects. Using Xenopus laevis we found that DYRK1A is
important for kidney development. Loss of dyrk1a in Xenopus leads to abnormal
kidney formation, which can be rescued by adding wild-type human DYRK1A
mRNA. Furthermore, we found that altered expression of Dyrk1a leads to altered
canonical Wnt signaling during Xenopus embryogenesis. This may suggest Dyrk1a
can alter Wnt signaling in other instances such as during nephrogenesis. This
dissertation fills a major gap in understanding how CAKUT arises in DYRK1A
syndrome patients and defines a novel protein involved in nephrogenesis and kidney
disease.
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CHAPTER 2: MATERIALS AND METHODS
This chapter is modified from Blackburn ATM, Bekheirnia N, Uma V, Corkins ME, Xu
Y, Rosenfeld JA, Bainbridge MN, Yang Y, Liu P, Madan-Khetarpal S, Delgado MR,
Hudgins L, Krantz I, Rodriguez-Buritica D, Wheeler PG, Al Gazali L, Mohamed
Saeed Mohamed Al Shamsi A, Gomez-Ospina N, Chao HT, Mirzaa GM, Scheuerle
AE, Kukolich MK, Scaglia F, Eng C, Rankin Willsey H, Braun MC, Lamb DJ, Miller
RK, Bekheirnia MR. DYRK1A-related intellectual disability syndrome: a novel
association with congenital anomalies of the kidney and urinary tract. Genetics in
Medicine. 2019 July 2. https://doi.org/10.1038/s41436-019-0576-0. Genetics in
Medicine establishes that authors retain copyright of their articles.

2.1 Constructs, Construct Design, and In Vitro Transcription
A pCS2-Xenopus-Dyrk1a-HA construct (158) was used in transcribing
Xenopus dyrk1a. Cloning for adding a GFP tag was executed by generating PCR
cDNA from a pCS2-Xenopus-Dyrk1a-HA construct (158) using a Bio-Rad C1000
Touch™ Thermal Cycler (Bio-Rad), following Addgene’s protocol for PCR cloning.
PCR with OneTaq (NEB) was used to amplify wild-type Xenopus dyrk1a excluding
the nucleotides coding for the stop codon. Forward primer 5’TTTGGATCCATGCATACAGGAGGAGAGAC-3’ was used to create the control
dyrk1a construct while forward primer 5’- TTTGGATCCATGAGACTTGAAAGAGGACGATGCATACAGGAGGAGAGAC-3’ was used to create the
dyrk1a + 5’ UTR construct, which added part of Dyrk1a’s endogenous 5’ UTR that is
recognized by the Dyrk1a MO. The same reverse primer 5’34

TTTTTTCTAGACGAGCTTGCCACAGGACTCTG-3’ was used to generate both
cDNA fragments. BamHI and XbaI were used to insert cDNA fragments into a pCS2GFP vector, placing the construct immediately upstream and in-frame with a GFP
tag. Cloning for the rescue experiment was executed by traditional cloning methods
and PCR cloning. The wild-type human DYRK1A cDNA was cut from the pMH-SFBDYRK1A construct (Addgene) and inserted into a pCS2-HA vector using XhoI and
contains a gateway vector site 5’ to the cDNA. PCR cloning was used to generate
the DYRK1AR205* variant. Site-directed mutagenesis was used to generate the
DYRK1AL245R variant. Forward primer 5’-AATGCGGAATTCAGACAAGTTTGTACAAAAAAGCAGGC-3’ and reverse primer 5’TAGAGGCTCGAGTCACACTTCTATC-TGTGCTTGATTCAG-3’ were used to
amplify the truncated cDNA plus the gateway vector site 5’ to the cDNA from the
wild-type human pCS2-HA-DYRK1A vector. Forward primer 5’CTGTCCTACAACCGCTATGACTTGCTG-3’ and reverse primer 5’CAGCAAGTCATAGCGGTTGTAGGACAG-3’ were used for site-directed
mutagenesis. The truncated cDNA was then inserted into a pCS2-HA vector using
EcoRI and XhoI sites. Prior to in vitro transcription, the reading frame of each
construct was confirmed by Sanger sequencing (Eurofins). The cDNA templates
were linearized for transcription using NotI. Capped mRNAs encoding the constructs
were generated using the SP6 mMessage mMachine Kit (Thermo Fisher Scientific).
The transcribed mRNA products were evaluated by a 1% agarose gel using RNA gel
loading dye and by optical density (OD 280/260) obtained from aNanoDrop® ND1000 Spectrophotometer (Thermo Fisher Scientific). For the p53 appendix, Mark E.
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Corkins generated the two point mutant constructs, C742T, p53 R248W and C844T,
p53 R282W, with site-directed mutagenesis from a wild-type human pCdna3-Flag-p53
vector with the following primers I designed: forward primer 5’-GGCGGCATGAACTGGAGGCCCATCCTCACCATCAT-3’ and reverse primer 5’-ATGGGCCTCCAGTTCATGCCGCCCATGCAGGAACT-3’ were used to create p53R248W while forward
primer 5’-CCTGGGAGAGACTGGCGCACAGAGGAAGAGAATCT-3’ and reverse
primer 5’-TCTGTGCGCCAGTCTCTCCCAGGACAGGCACAAAC-3’ were used to
create p53 R282W.

2.2 Western Blots
Ten-twenty embryos were collected at various stages (159) to make protein
lysates as previously described (160). One embryo equivalent of lysate was run in
each well of a 7.5% or 10% SDS-PAGE gel. Protein was transferred onto a 0.45 µm
PVDF membrane (Thermo Fisher Scientific) and blocked for 1 hour at room temp or
overnight in KPL block (SeraCare) at 4°C. Blots were incubated one of the
antibodies listed: rabbit anti-green fluorescent protein (anti-GFP) (1:500, iclLab),
rabbit anti-β-catenin (1:1000, McCrea lab), mouse anti-HA (1:1000, Sigma 12CA5),
anti-active β-catenin (1:1000, Cell Signaling 8814), mouse anti-p53 (1:1000, Abcam
ab16465), mouse anti-Flag (1:1000, Sigma M2), or rabbit anti-glyceraldehyde 3phosphate dehydrogenase (anti-GAPDH) (1:1000, Santa Cruz) for 3 hours at room
temperature or for 24 hours at 4°C. Blots were washed with TBS-T, incubated in
goat anti-rabbit or goat anti-mouse IgG horseradish peroxidase secondary antibody
(1:3000; Bio-Rad) for 1 hour at room temperature, and washed again with TBS-T
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prior to imaging with Bio-Rad ChemiDoc XRS+ (Bio-Rad) using SuperSignal West
Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific). To validate
knockdown of protein expression by Dyrk1a MO or p53 MO, Western blot analysis
was carried out on lysates derived from embryos injected at the single cell stage.
Forty ng of either Dyrk1a morpholino 5’- TGCATCGTCCTCTTTCAAGTCTCAT-3′
(Gene Tools LLC) (158), or standard morpholino 5′-CCTCTTACCTCAGTTACAATTTATA-3′ (Gene Tools LLC) was co-injected with 1 ng mRNA (either Xenopus
dyrk1a control, or Xenopus dyrk1a + 5’ UTR) along with 1 ng membrane-RFP RNA
(161). For p53 knock down, the same dose of 40 ng for either p53 MO 5’GCCGGTCTCAGAGGAAGGTTCCATT-3’ (Gene Tools LLC) or standard MO was
injected into embryos and analyzed by Western blot. For p53 knockout, 500 ng of
either sgRNA p53.1 5’- CTAGCTAATACGACTCACTATAgGTAACAGCTCCTGTATGGGAgTTTTAGAGCTAGAAATAGCAAG-3’ sgRNA p53.2 5’- CTAGCTAATACGACTCACTATAggCGCGGCTCCATTCTCCGGGCTAgTTTTAGAGCTAGAAATAG
CAAG-3’ or slc45a2 control 5’-CTAGCTAATACGACTCACTATAggTTACATAGGCTGCCTCCAgTTTTAGAGCTAGAAATAGCAAG-3’ plus 1 ug of Cas9 protein and a
lineage tracer were injected into single cell embryos. Lysates were made from 10
embryos at stage 10-11. Underlined sequence is the guide sequence designed from
CHOPCHOP.cbu.uib.no.

2.3 Design and Statistical Analyses
Error bars represent standard error of experiments that were repeated four to
eight times. The total number of Xenopus embryos and significance are as follows:
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(Figure 12F) Control: 166, Dyrk1a MO + β-gal: 125, Dyrk1a MO + DYRK1A: 140,
Dyrk1a MO + DYRK1AR205*: 94. * (asterisk) = p<0.001 comparing individual
experimental groups to Standard MO + β-gal. # (pound sign) = p<0.006 comparing
Dyrk1a MO + DYRK1A to Dyrk1a MO + DYRK1AR205*. (Figure 12G) Control: 75,
Dyrk1a MO + β-gal: 80, Dyrk1a MO + DYRK1A: 57, Dyrk1a MO + DYRK1AL245R: 74.
* (asterisk) = p<0.001 comparing Standard MO + β-gal to Dyrk1a MO + β-gal or
Dyrk1a MO + DYRK1AL245R. # (pound sign) = p<0.05 comparing Dyrk1a MO +
DYRK1A to Dyrk1a MO + DYRK1AL245R. As expected, no statistical difference was
seen between Dyrk1a MO + β-gal and Dyrk1a MO + DYRK1AR205* or Dyrk1a MO +
DYRK1AL245R. Statistical significance was established using a two-tailed T-test.
(Figure 12J) The graph demonstrates a significant difference in edema and kidney
abnormalities in embryos injected with either Standard MO or Dyrk1a MO. Error bars
represent standard error of experiments that were repeated three times. The total
number of Xenopus embryos and significance are as follows: Dyrk1a MO: 114 total,
45 of which had edema, Standard MO: 97 total, 2 of which had edema. * (asterisk) =
p<0.008 comparing Standard MO to Dyrk1a MO embryos with edema, defects in
one, and defects in both kidneys. Statistical significance was established using a
two-tailed T-test.

2.4 Study Participants
The index patient was seen in the Renal Genetics Clinic (RGC) at Texas
Children’s Hospital. Subsequently, patients who had exome sequencing in a clinical
diagnostic laboratory (Baylor Genetics) were queried for de novo (except P1, P12,
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and P15) pathogenic (except P10 [likely pathogenic], and P5, P7, and P17, called as
variants of uncertain significance in the initial report) variants in DYRK1A. Inclusion
criteria also included (1) variant confirmation using Sanger sequencing, and (2) lack
of other variants that could explain the phenotype observed. Exclusion criteria
included multiple additional candidate genes that may be related to the phenotype.
The final size of our cohort after applying those filters was 19 patients. Clinical
phenotype information was collected from initial exome sequencing requisition form
or contacting referring physicians. The Institutional Review Board at Baylor College
of Medicine approved the study protocol for the Protection of Human Subjects.
Consent was obtained for clinical genetic testing/exome sequencing from each
family participating in this study.

2.5 Exome Sequencing and Data Analysis
Exome sequencing was performed by previously published methods at Baylor
Genetics (162–164). In brief, an Illumina paired-end precapture library was
constructed with 1 ug of DNA, according to the manufacturer’s protocol (Illumina
Multiplexing_SamplePrep_ Guide _- 1005361_D), with modifications as described in
the BCM- HGSC Illumina Barcoded Paired-End Capture Library Preparation protocol
(162). Four precaptured libraries were pooled and then hybridized in solution to the
HGSC CORE design (52 Mb, NimbleGen) according to the manufacturer’s protocol
(NimbleGen SeqCap EZ Exome Library SR User’s Guide Version 2.2), with minor
revisions. Sequencing was performed in paired-end mode with the Illumina HiSeq
2000 platform, with sequencing-by-synthesis reactions extended for 101 cycles from
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each end with an additional cycle for the index read. With a sequencing yield of 12
Gb, 92% of the targeted exome bases were covered to a depth of 20x or greater.
Illumina sequence analysis was performed with the HGSC Mercury analysis pipeline
(https://www.hgsc.bcm.edu-/software/mercury), which moves data through various
analysis tools from the initial sequence generation on the instrument to annotated
variant calls (SNVs and intraread indels). Variant interpretation was performed
according to the most recent guidelines published by the American College of
Medical Genetics and Genomics (ACMG) (165). Accordingly, only variants that met
strict criteria were called pathogenic. Sanger sequencing confirmed all variants
reported in this dissertation.

2.6 Whole Mount In Situ Hybridization
A Digoxygenin-11-UTP RNA labeling kit was used to generate digoxigeninlabeled RNA probes for in situ hybridization.Digoxygenin-11-UTP labeled antisense
RNA probe for dyrk1a was synthesized from Xenopus Genome Collection IMAGE
clone 7687837 (166) using SalI restriction enzyme and T7 polymerase. This clone
carries the Xenopus tropicalis coding sequence for dyrk1a, therefore both X.
tropicalis and X. laevis embryos were stained to ensure proper detection of the
target. RNA probe atp1a1 was synthesized using SmaI restriction enzyme and T7
polymerase (167). Embryos were staged, fixed, and stained according to standard
procedures (168, 169) using an anti-digoxygenin antibody (1:3000, Sigma
11093274910) and BM Purple (Sigma 11442074001).
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2.7 Xenopus laevis Embryos and Microinjections
Xenopus eggs were obtained by standard means, placed in 0.3x MMR and
fertilized in vitro (169). Blastula cleavage stages and dorsal versus ventral polarity
were determined by established methods (168). Microinjections were targeted to the
V2 blastomere at the eight-cell stage, which provides major contributions to the
development of the pronephros (115, 168, 170). Ten nL of injection mix (described
below) was injected into embryos. Ten ng of Dyrk1a morpholino 5’-TGCATCGT
CCTCTTTCAAGTCTCAT-3′ (171) or Standard morpholino 5′CCTCTTACCTCAGTTACAATTTATA-3′ was co-injected with 50 pg mRNA (either
control β-galactosidase, wild-type human DYRK1A, DYRK1AR205*, or DYRK1AL245R)
along with 1 ng membrane-RFP mRNA (161) as a lineage tracer to verify that the
correct blastomere was injected.

2.8 Immunostaining
Embryos were staged (168), fixed, and immunostained (172) using
established protocols. Proximal tubule lumens were labeled with the antibody 3G8
(1:30, European Xenopus Resource Centre, Portsmouth, UK), while the cell
membranes of distal and connecting tubules were labeled with antibody the 4A6
(1:5, European Xenopus Resource Centre) (173). Rabbit anti–red fluorescent protein
(anti-RFP) (1:250, MBL International) antibody was used to detect the RFP tracer.
Goat anti-mouse or anti-rabbit conjugated to Alexa Fluor 488 or Alexa Fluor 555
(1:500, Invitrogen) secondary antibodies were used to visualize antibody staining.
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2.9 Imaging
Embryos used for in situ hybridization were imaged on a Zeiss AxioZoom V16
with a 1x objective, Zeiss 512 color camera (Zeiss), and extended depth of focus
processing. Embryos used for immunostaining were scored and photographed using
an Olympus SZX16 fluorescent stereomicroscope and Olympus DP71 camera
(Olympus); 3G8/4A6 immunostained kidney images were taken using a Zeiss
LSM800 confocal microscope (Zeiss). Fixed embryos were cleared with
BABB/Murray’s clearing solution for confocal imaging (1:2 volume of benzyl alcohol
to benzyl benzoate). Images were processed with Adobe Photoshop.

2.10 Transgenic Xenopus Lines
Xla.Tg(actc1:GFP)Mohun (NXR_0007) is a cardiac actin:GFP transgenic line
where 580bp of Xenopus laevis actc1b gene drives GFP expression. GFP is found
in the embryonic striated muscle. Expression can be seen in the somites,
craniofacial structures, and the heart.
Xla.Tg(WntREs:dEGFP)Vlemx (NXR_0064) also known as pbin7LEF-GFP/Wnt
Reporter. The construct contains a minimal TATA box, a synthetic Wnt-responsive
promoter which consists of 7 copies of a TCF/LEF1 binding DNA element, and a
reporter gene which encodes destabilized EGFP and a polyA sequence. GFP
expression consists of dynamic patterns of Wnt/β-catenin signaling activity.
Xla.Tg(CMV:hist2h2be-RFP)Ueno (NXR_0073). The construct contains a CMV
promoter, Xenopus laevis Histone 2B, and RFP in a pCS2p+ plasmid. Histone 2B
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drives the RFP expression, which is found only in the nucleus. RFP is found in all
nuclei, but distinct RFP expression outlines the somites.
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CHAPTER 3: DYRK1A-RELATED INTELLECTUAL DISABILITY SYNDROME: A
NOVEL ASSOCIATION WITH CONGENITAL ANOMALIES OF THE KIDNEY AND
URINARY TRACT
This chapter is modified from Blackburn ATM, Bekheirnia N, Uma V, Corkins ME, Xu
Y, Rosenfeld JA, Bainbridge MN, Yang Y, Liu P, Madan-Khetarpal S, Delgado MR,
Hudgins L, Krantz I, Rodriguez-Buritica D, Wheeler PG, Al Gazali L, Mohamed
Saeed Mohamed Al Shamsi A, Gomez-Ospina N, Chao HT, Mirzaa GM, Scheuerle
AE, Kukolich MK, Scaglia F, Eng C, Rankin Willsey H, Braun MC, Lamb DJ, Miller
RK, Bekheirnia MR. DYRK1A-related intellectual disability syndrome: a novel
association with congenital anomalies of the kidney and urinary tract. Genetics in
Medicine. 2019 July 2. https://doi.org/10.1038/s41436-019-0576-0. Genetics in
Medicine establishes that authors retain copyright of their articles.

3.1 Introduction
Intellectual disability and autism spectrum disorder (ASD) are heterogeneous
neurodevelopmental disorders (NDDs) both clinically and genetically (174).
Understanding NDDs is important, as they affect more than 3% of children
worldwide (175). There over 1000 loci that attribute to NDDs and because of this
genetic heterogeneity there are a limited number of recurrent mutations (175).
Though a number of genes have been found to reoccur in NDDs, in 50% of cases
the cause remains elusive (175). The advent of whole genome and whole exome
studies have led to a significant number of de novo mutations in novel candidate
genes (176). Between three studies with 8,400 individuals, mutations in DYRK1A
accounted for 0.1%-0.5% of individuals with NDDs (145, 177–179).
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The DYRK family of protein kinases are conserved across species from lower
eukaryotes to mammals (135). DYRK family members are activated by
autophosphorylating a tyrosine residue in their activation loop (136). DYRK1A is the
most extensively characterized member of the DYRK family, which in humans, is
encoded by the DYRK1A gene located in the Down syndrome critical region of
chromosome 21 (137).
A growing body of literature implicates a strong causal relationship between
DYRK1A haploinsufficiency and a recognizable syndrome known as DYRK1Arelated intellectual disability syndrome (137, 145, 179). This syndrome is rare and
was first described in medical literature in 2008 (rarechromo.org). In addition to ASD
and intellectual disability, other frequently occurring features include intrauterine
growth restriction, difficulty feeding with failure to thrive, microcephaly, seizures,
dysmorphic facial features, and developmental delays (145), while additional
phenotypic features are observed less commonly such as cardiac anomalies (145,
180). Though previous literature has reported incidental genitourinary findings
including micropenis, hydronephrosis, pelvic kidney, renal cysts, and unilateral renal
agenesis (180), no studies have explored if these anomalies are a direct result of
DYRK1A loss.
This dissertation presents a cohort of individuals with de novo (when both
parental samples available) DYRK1A single-nucleotide variants (SNVs) or small
deletions ≤10 base pairs and defines CAKUT and genital defects in DYRK1A
syndrome patients. I also provide supporting evidence using Xenopus embryos as a
model that DYRK1A, which is expressed in embryonic nephrons, is required for
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genitourinary development and that two pathogenic variants of human DYRK1A are
likely responsible for the CAKUT/genital defects phenotype. Together, these findings
support the investigation of potential CAKUT/genital defects in the clinical workup of
patients with DYRK1A-related intellectual disability syndrome.

3.2 RESULTS
3.21 CAKUT/Genital Defects Identified in Patients with DYRK1A Variants
The index patient which prompted our research was seen in the Renal
Genetics Clinic for the evaluation of intellectual disability, global developmental
delay, hypospadias, and congenital chordee. Trio exome sequencing revealed a
novel de novo pathogenic p.G168fs single base pair deletion in DYRK1A. A
subsequent query of the exome sequencing database at Baylor Genetics revealed a
total of 18 additional individuals with SNVs or deletions ≤10 base pairs (as defined in
“Materials and Methods”) in DYRK1A among approximately 8000 probands.
Phenotype and molecular information of these patients are summarized in Table 2
and Figure 6. Probands were mostly children ranging from 2 to 27 years of age. All
19 of these individuals had neurodevelopmental phenotypes consistent with loss-offunction of DYRK1A (MIM 614104). All referring physicians were subsequently
contacted to obtain further details regarding the CAKUT/genital defect phenotypes.
However, CAKUT/genital defect status of four patients remain unknown. Eleven of
fifteen (73%) individuals with available information presented with CAKUT, including
unilateral renal agenesis and/or genital defects including undescended testis and
hypospadias (Table 3). One patient (P6) with unilateral renal agenesis was identified
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Table 2. Demographics, Molecular Data, and Phenotype of 19 Patients with SNVs
and Small Indels (<10bp) in DYRK1A Identified by Clinical Exome Sequencing.
ASD: Autism spectrum disorder (HP:0000717), DD: Developmental delays; Global (G; HP:
0001263), Motor (M; HP:0001270), Speech (S; HP:0000750), Unspecified (U), DF/FTT:
Difficulty feeding (HP:0011968)/ failure to thrive (HP:0001508), FD: Facial dysmorphism
(HP:0001999), GU: Genitourinary; Normal renal ultrasound: nRUS, Unknown: ukn, +
denotes phenotype observed (see Table 3 for more details), ID: Intellectual disability
(HP:0001249). M/F: male/female. Note that the age is in years. * Denotes published
patients. Used with permission from Reza and Nasim Bekheirnia, who made the table.
Rachel Miller and I edited the table.

48

Figure 6. Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) Associated
with DYRK1A Variants in Patients with DYRK1A-Related Intellectual Disability
Syndrome.
Schematic shows the DYRK1A protein domains. Shapes, which identify the type of variant
(squares = frame shift variants, circles = missense variants, stars = nonsense variants,
triangles = splice variants), are positioned where DYRK1A patient variants impact the amino
acid sequence. Patient variants are labeled by patient number as listed in Tables 2 and 3.
Variants that result in CAKUT are red, those that do not result in CAKUT are blue, and those
in which the effects on CAKUT status are unknown are black. Protein domains are
abbreviated as follows: DH; DYRK homology box; HIS histidine; NLS nuclear localization
signal; PEST proline (P), glutamic acid (E), serine (S), and threonine (T); Ser/Thr
serine/threonine. Inset shows highly conserved sequence surrounding the activation loop
(labeled in orange) of the kinase domain. GU; genitourinary. Used with permission from
Rachel Miller who made the figure.
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Case
#

SNV

Segregation

Renal or GU Phenotype

P1

p.N151fs

Mother negative,
father's sample
unavailable

Mild unilateral pelviectasis
(HP:0010946) and frequent UTIs
(HP:0000010)

P2

p.K154fs

De Novo

Genital anomalies (HP:0000078)

P3

p.L164fs

De Novo

Kidney abnormalities (not specified;
HP:0000077)

P4

p.G168fs

De Novo

Hypospadias (HP:0000047), micropenis
(HP:0000054), and congenital chordee
(HP:0000041)

P5

p.V173F

De Novo

Renal ultrasound is normal with normal
genitalia on exam

P6

p.R205X

De Novo

Left renal agenesis (HP:0000122)

P7

p.L245R

De Novo

Left renal agenesis (HP:0000122)

P8

p.R263X

De Novo

Shawl scrotum (HP:0000049) and
history bilateral orchiopexy
(HP:0000028)

P9

p.S329fs

De Novo

Hypospadias (HP:0000047) and kidney
abnormalities (tiny echogenic foci)

P10

p.G348R

De Novo

Normal renal ultrasound

P11

c.1098+1G>
A

De Novo

Unknown

P12

p.A388fs

Mother negative,
Father is mosaic

Frequent UTI (HP:0000010)

P13

p.K406fs

De Novo

Unknown

P14

p.R437X

De Novo

Unknown

P15

p.R437X

Mother negative,
father's sample
unavailable

Normal renal ultrasound

P16

p.R437X

De Novo

Normal renal ultrasound

P17

p.R467Q

De Novo

Unknown

P18

p.R467X

De Novo

Orchiopexy (HP:0000028) and inguinal
hernia (HP:0000023)
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P19

p.S494fs

De Novo

Bilateral inguinal hernias (HP:0000023)
but no renal ultrasound

Table 3. Available information About Genitourinary Phenotype of Patients Reported in
This Study.
Eleven patients have genitourinary phenotype. This strongly suggests an important role for
DYRK1A in genitourinary tract development. Used with permission from Reza and Nasim
Bekheirnia, who made the table. Rachel Miller and I edited the table.
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after this newly acquired association of DYRK1A with CAKUT was discussed with
the referring physician (181). The probability of loss-of-function intolerance (pLI)
score of DYRK1A is 1, indicating that this gene is intolerant to loss-of-function
variants (182).

3.22 A Majority of the Variants Found in DYRK1A Are Loss-of-Function and are
Found in the Kinase Domain
Many of the variants found in this cohort are found in the kinase domain
(14/17 [82%]), which spans from residues 159 to 479, and 11/17 (65%) are thought
to undergo nonsense-mediated decay (NMD), as they result in premature stop
codons (https://nmdpredictions.shinyapps.io/shiny/) (Figure 6). Of the remaining six
variants, one affects splicing, one escapes NMD (p.S494fs), and four are missense
variants. The four missense variants are all found in the kinase domain in four
individuals. Of these four individuals with missense variants, P7 was diagnosed with
unilateral renal agenesis (p.L245R), P5 and P10 had normal renal ultrasounds
(p.V173F and p.G348R), and P17 has an unknown CAKUT status (R467Q).
Because these variants still lead to other DYRK1A syndrome features such as
intellectual disability, they may be important for the catalytic activity or
conformational stability of DYRK1A. In fact, in a separate DYRK1A structural study
the R467Q variant was found to be a part of a network of electrostatic interactions
thought to play a role in the stability of the DYRK1A protein (183). Additionally, the
L245R variant was found to prevent autophosphorylation of DYRK1A’s activation
loop in HEK293 cells (184) and was shown to be catalytically inactive via an in vitro
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kinase assay (185). Of the three variants not found in the kinase domain, two are
just N-terminal (N151fs, K154fs) and the last is found just C-terminal (to kinase
domain) in the PEST domain (S494fs). Although theoretically all variants that are
more N-terminal should result in NMD, a majority of the variants reside in the kinase
domain for unknown reasons that should be studied further.

3.23 Xenopus laevis as a Model of Genitourinary Development
DYRK1A’s amino acid sequence is highly conserved among amniotes
(https://www.ncbi.nlm.nih.gov/homologene). Even though the N- and C-terminal
regions diverge in invertebrates, the amino acid sequence of the kinase domains are
similar indicating the importance of this protein throughout evolution. To model
CAKUT associated with human DYRK1A loss-of-function variants using Xenopus
embryos, I first analyzed the conservation of the whole DYRK1A protein sequence,
focusing on the kinase domain. Human and Xenopus DYRK1A proteins are 91.3%
identical over the entire amino acid sequence (Figure 7A). Additionally, the kinase
domain, which is where a majority of the variants that cause CAKUT in this study are
found, is 97.5% identical to the human protein (Figure 7A). Importantly, the human
and Xenopus kinase activation loop sequence, which are essential for the kinase
activity of DYRK1A, are identical.
Xenopus is a great model for many reasons. Their embryonic kidney, the
pronephros, can easily be visualized and imaged through a transparent epidermis,
and they develop a fully functional kidney in ~56 hours (15). Xenopus was chosen

53

54

Figure 7. Human and Xenopus laevis Protein Alignment and Short and Long Xenopus
Homeolog Alignment for dyrk1a 5’UTR.
(A) Human DYRK1A mRNA transcript variant 1 (NM_001396.4) and Xenopus laevis dyrk1a
short homeolog mRNA (NM_001163197.1) were translated and aligned using Clustal
Omega. The overall identity between the protein sequences is 91.3% while the kinase
domain has 97.5% identity demonstrating that DYRK1A is highly conserved. Grey shading
represents the kinase domain of DYRK1A. Symbols reflect Clustal Omega’s analysis of the
residues and examples of specific residue groups that reflect each symbol can be found at
their website https://www.ebi.ac.uk/Tools/msa/clustalo/. An * (asterisk) indicates positions
with a fully conserved residue. A : (colon) indicates conservation between groups of strongly
similar properties. A . (period) indicates conservation between groups of weakly similar
properties. DYRK1A encodes a protein of 763 or 754 amino acid residues which results
from alternative splicing with the longer isoform representing the canonical sequence shown
above. Xenopus is missing residues 70-78 which are the same residues the short isoform of
human DYRK1A (754 amino acids) is missing. This suggests that Xenopus most likely
expresses an isoform of DYRK1A that is orthologous to the short isoform
(NM_001347721.2) in humans. (B) Alignment of dyrk1a’s 5’UTR demonstrate in grey
shading where the morpholino targets and that it hits both long and short homeologs in
Xenopus. Underlined text represents the coding sequence of dyrk1a. The Dyrk1a MO was
designed against the short homeolog of dyrk1a (top sequence), however, here it is shown it
targets both the short and long (bottom sequence) (identified via a BLAT search of Crick
http://genomes.crick.ac.uk/). The MO does not target dyrk1a.2 which appears to be a
duplication of dyrk1a with amino acid conservation only maintained in the kinase domain.
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because it is an established model of nephron development, and gene expression
studies demonstrate that the developing Xenopus nephron is anatomically and
functionally similar to the mammalian nephron (13, 28, 186). The embryonic
pronephros is the precursor to the mesonephric and metanephric kidney in
mammals, and subsequent genitourinary development is dependent upon this
structure (Figure 1). Specifically, as the pronephros extends toward the cloaca, the
mesonephric nephrons form adjacent to the elongating nephric duct, also known as
the Wolffian duct (Figure 1) (187). The ureteric bud, which is required for the
development of the collecting duct system in mammals, then branches from this
duct. Because the Wolffian duct is required for genitourinary development in males
and Müllerian duct elongation, which is necessary for normal female anatomy,
depends upon the development of the Wolffian duct (188, 189), the development of
the pronephros is critical to both renal and genital development in mammals. Thus,
although it is not a well-established model for studying genital formation, the
Xenopus pronephros is essential for development of the mesonephric/Wolffian duct
and subsequently the Müllerian duct, which are required for genitourinary
development (190, 191).

3.24 dyrk1a is Expressed in the Xenopus Kidney and in Vivo Knockdown
Demonstrates its Role in Kidney Development.
To assess whether dyrk1a is expressed in the Xenopus kidney, in situ
hybridization was performed across developmental stages in both X. laevis and X.
tropicalis (Figure 8). dyrk1a expression is seen in the pronephros in several stages
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Figure 8. In situ Hybridization of Dyrk1a Across Developmental Stages Demonstrates
Kidney Expression in X. laevis and X. tropicalis.
To demonstrate spatial-temporal expression of dyrk1a in the kidney, in situ hybridization
was performed. Given that the RNA probe was designed against the X. tropicalis sequence,
both species were analyzed. Pronephric kidney development occurs between stages 12.5
and 40, which is demonstrated in A-F for Xenopus laevis and G-I for Xenopus tropicalis.
Expression of dyrk1a can be visualized in stage 26-40 embryos suggesting Dyrk1a may be
important for kidney development. For clarity, insets (D’ and J’) for stage 30/31 tadpole
kidneys with 200 μm scale bars have been added. All other scale bars represent 1000 μm.
Used with permission from Helen Wilsey and Yuxiao Xu, who made the figure. I made
editions to the figure, as well.
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of both X. laevis and X. tropicalis, a closely related species to X. laevis, during
kidney development, suggesting that it may be important for nephrogenesis.
Furthermore, Dyrk1a protein expression can be seen in the kidney in later stage
Xenopus tadpoles (Figure 9) which may suggest it is important for kidney
maintenance.
To examine dyrk1a’s role in renal development in Xenopus laevis, an
antisense MO that blocks translation was used to knock down endogenous Dyrk1a
protein expression. Xenopus laevis has two copies of the dyrk1a gene because of its
allotetraploid genome. Both dyrk1a transcripts are targeted by the Dyrk1a MO used
in this study (Figure 7B). Two constructs, a control and the experimental construct,
were generated with a GFP tag to demonstrate that the MO targets the endogenous
5’ untranslated region of dyrk1a’s transcript (Figure 10A). Western blot analysis was
then used to confirm that the MO correctly targets Xenopus dyrk1a mRNA (Figure
10B). Furthermore, knockdown experiments were used to determine whether loss of
Dyrk1a function in Xenopus results in disruption of kidney development. Embryos
were injected in a single V2 blastomere to target a single kidney, leaving the other
as an internal control. First, Knockdown with the Dyrk1a MO resulted in loss of
proximal tubule convolution by in situ hybridization with late kidney marker NA+K+ATPase (Figure 11B). In addition, Dyrk1a knockdown resulted in abnormal
pronephroi when immunostained with antibodies 3G8 and 4A6, which label the
proximal tubules and the distal and connecting tubules (nephric duct), respectively
(Figure 12B). Loss of Dyrk1a primarily lead to loss of the proximal and distal
tubules, with defects in the connecting tubules (nephric duct) occurring only in
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A
B

Figure 9. Immunofluorescence of Dyrk1a in Xenopus laevis at Stage 47 Demonstrates
it is Expressed in the Kidney.
(A) Immunofluorescence shows that the Dyrk1a protein is expressed in later stages of
tadpoles in the brain, craniofacial structures, and the kidney (outlined by white rectangles)
by dissection scope. (B) Confocal microscopy further demonstrates that Dyrk1a is localized
to the cytoplasm at this stage and does not co-localize with DAPI which stains the nucleus.
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Figure 10. The Dyrk1a MO Correctly Targets Xenopus dyrk1a mRNA and Wild-Type,
Missense, and Truncated Human DYRK1A Proteins are Expressed in Neurula Stage
Xenopus Embryos.
Two constructs were generated with a GFP tag to demonstrate that the MO targets the
endogenous 5’ untranslated region (UTR) of dyrk1a’s transcript. (A, bottom) Schematic
demonstrates that the 5’ UTR construct contains part of dyrk1a’s endogenous (endo) 5’ UTR
that is recognized by the Dyrk1a MO (A, top) while the control construct does not. (B)
Single-cell embryos were injected with 10 ng of either Dyrk1a MO or Standard MO (Std MO)
and co-injected with 1 ng mRNA (either Xenopus dyrk1a control, or Xenopus dyrk1a + 5’
UTR). Western blot analysis demonstrates complete reduction of GFP protein levels,
indicative of loss of exogenous Dyrk1a in neurula stage embryos injected with Dyrk1a MO
and dyrk1a + 5’ UTR mRNA (lane 5) compared to the Standard MO and dyrk1a + 5’ UTR
(lane 4) and Standard MO or Dyrk1a MO and dyrk1a control mRNA (lane 2, lane 3). GAPDH
was used as a loading control. (C) Wild-type human DYRK1A cDNA was inserted into a
pCS2-HA vector. DYRK1AR205* and DYRK1AL245R variants were generated from the wild-type
human pCS2-HA-DYRK1A vector. Western blot demonstrates HA protein is present in wildtype, missense (lanes 2 and 3 ~95 kDa), and truncated DYRK1AR205* (lane 4 ~25 kDa)
lanes, demonstrating Xenopus neurula stage embryos can successfully translate human
DYRK1A mRNA. GAPDH was used as a loading control. Bar under the molecular weight
indicates its position on the blot.
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Figure 11. Dyrk1a Knockdown Disrupts Late Kidney Marker Na+K+-Atpase (atp1a1) in
Xenopus.
Embryos were unilaterally injected at the 8-cell stage with 10 ng of Dyrk1a MO and
compared to uninjected embryos. In situ hybridization was performed on stage 40 tadpoles
which were probed with the late kidney marker Na+K+-Atpase (atp1a1) which binds to the
entire kidney. (A) Uninjected kidneys appear normal whereas (B) distinct proximal tubule
loss can be seen in embryos injected with the Dyrk1a MO.
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Figure 12. Loss of Dyrk1a results in Kidney Anomalies in Xenopus laevis.
(A'–E’) Embryos were unilaterally injected at the 8-cell stage with 10 ng of Dyrk1a
MO or standard MO (Std MO) along with 50 pg β-galactosidase (β-gal), wild-type,
DYRK1AR205*, or DYRK1AL245R mRNA. Stage 40 tadpoles were stained with kidney
antibodies 3G8, which labels the proximal tubules, and 4A6, which labels the distal and
connecting tubules. Letters without apostrophes (A–E) represent the injected side, whereas
letters with apostrophes (A’–E’) represent the uninjected side. (B) Knockdown with a
translation-blocking Dyrk1a MO disrupts kidney development, which can be partially rescued
(C) by co-injecting with wild-type human DYRK1A mRNA but not (D–E) DYRK1AR205* or
DYRK1AL245R mRNA. (A) Co-injection of a standard MO and β-gal serves as a negative
control. Scale bars represent 100 μm. (F) The graph demonstrates a significant difference
between embryos injected with either Dyrk1a MO+β-gal or Dyrk1a MO+DYRK1AR205* versus
with Dyrk1a MO+DYRK1A suggesting successful rescue with human DYRK1A but not with
the nonsense mRNA. (G) The second graph demonstrates a significant difference between
embryos injected with Dyrk1a MO+DYRK1AL245R versus with Dyrk1a MO+DYRK1A, which
suggests that the missense mRNA also fails to rescue the kidney phenotype. Significance
was established against embryos that had a moderate or severe kidney phenotype (orange
bar) and excluded embryos that had a weak phenotype (yellow bar). (F) Asterisk (*)
indicates p < 0.001 comparing individual experimental groups with standard MO+β-gal.
Pound sign (#) indicates p < 0.006 comparing Dyrk1a MO+DYRK1A with Dyrk1a
MO+DYRK1AR205*. (G) Asterisk (*) indicates p < 0.001 comparing standard MO+β-gal with
Dyrk1a MO+β-gal or Dyrk1a MO+DYRK1AL245R. Pound sign (#) indicates p < 0.05
comparing Dyrk1a MO+DYRK1A with Dyrk1a MO+DYRK1AL245R. For edema assays,
embryos were injected at the 4-cell stage in both ventral cells to target both kidneys while
avoiding the dorsal cells fated to become the heart and liver, which can also lead to edema.
(H) Embryos injected with the standard MO did not develop edema while embryos injected
(I) with the Dyrk1a MO did develop edema and also suffered from abnormal kidney
formation. (J) The graph demonstrates a significant difference in edema and kidney
abnormalities in embryos injected with either standard MO or Dyrk1a MO. Asterisk (*)
indicates p < 0.008 comparing standard MO with Dyrk1a MO embryos with edema, defects
in one, and defects in both kidneys. Error bars represent standard error. For ease of
comparison of (n) and p-values across conditions, please refer to Tables 4–6.
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Figure 12F

Standard
MO
+ β-gal

Dyrk1a
MO
+ β-gal

Dyrk1a MO
+ WT
DYRK1A

Dyrk1a MO
+ DYRK1A
R205*

166

125

140

94

1

3.42E-08

0.0008

5.98E-07

1

0.0051

0.5867

1

0.0055

Xenopus embryo
Standard
MO
Dyrk1a
MO
Dyrk1a
MO
Dyrk1a
MO

1
*

Table 4. Figure 12F p-values for each experimental condition as determined by twotailed T-test.
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Table 5. Figure 12G p-values for each experimental condition as determined by twotailed T-test.

Xenopus embryo (n)
Edema (n)
2 abnormal kidneys
1 abnormal kidney (n)

Standard MO

Dyrk1a MO

97
2
0
1

114
45
31
14

Table 6. Xenopus embryos used for edema experiment.
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embryos with a more severe phenotype.

3.25 Variants Identified in DYRK1A-Related Intellectual Disability Syndrome
Fail to Rescue Dyrk1a Loss-of-Function in Xenopus
To assess if patient DYRK1A variants lead to pronephric anomalies as they
do in Xenopus, rescue experiments were carried out upon MO-mediated Dyrk1a
knockdown in Xenopus. To express human DYRK1A in Xenopus, three constructs
with HA tags were generated: wild-type human DYRK1A, a truncating patient variant
DYRK1AR205*, and a missense patient variant DYRK1AL245R. Western blot analysis
was used to confirm that the wild-type human DYRK1A and DYRK1AL245R, ~95 kDa,
and the truncated human DYRK1AR205* mRNA constructs, ~25 kDa, could be
successfully expressed in Xenopus (Figure 10C). Overexpression of the rescue
dose (50 pg) of either β-galactosidase (β-gal), wild-type DYRK1A, DYRK1AR205*, or
DYRK1AL245R mRNA demonstrated no gain-of-function phenotype of either DYRK1A
variant (Figure 13). The kidney anomalies caused by Dyrk1a knockdown were
partially rescued by co-injecting wild-type human DYRK1A mRNA (Figure 12C).
However, neither DYRK1AR205* or DYRK1AL245R mRNA rescued these anomalies
(Figure 12D, E). Due to many factors, rescue experiments rarely give a full rescue.
Therefore, significance for Figure 12 was established against embryos that had a
moderate or severe kidney phenotype (orange bar) and excluded embryos that had
a weak phenotype (yellow bar). Detailed descriptions of how embryos kidney
severities are scored can be found in Figure 14.
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Figure 13. Overexpressing Wild-type DYRK1A, DYRK1AR205* or DYRK1AL245R Does Not
Cause a Gain-of-Function Phenotype.
(A) Xenopus embryos were injected at the 8-cell stage with the rescue dose (50 pg) of either

-gal, wild-type DYRK1A, DYRK1AR205*, or DYRK1AL245R mRNA. (B) No significant
difference (p>0.7) was found between either -gal and wild-type DYRK1A, DYRK1AR205*, or
DYRK1AL245R suggesting neither variant elicits a gain-of-function phenotype. It should be
noted that some embryos injected with wild-type human DYRK1A mRNA had slightly
underdeveloped kidneys suggesting DYRK1A overexpression may also affect kidney
development. Experiments were repeated three times with error bars representing standard
error. The total number of Xenopus embryos are as follows: β-gal: 67, DYRK1A: 76,
DYRK1AR205*: 88, DYRK1AL245R: 65. Scale bar represents 100 µm.
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Figure 14. Scoring System for Xenopus Embryonic Kidneys.
Kidneys were scored at Nieuwkoop and Faber stage 40 (168). (A) A normal kidney consists
of three branches in the proximal region with a “trunk” connecting to the convoluted looping
of the early distal region, and strong immunostaining of the late distal region. (B) A weak
phenotype consists of loss of one of the branches in the proximal region and possibly less
early distal looping and/or partial loss of late distal immunostaining. (C) A moderate
phenotype consists of loss of two of the branches in the proximal region with moderate loss
of early distal looping and possible loss of late distal immunostaining. (D) A severe
phenotype consists of complete loss of proximal tubules with severe or complete loss of
early distal looping and the late distal region. (E) The schematic represents a stereotypical
Xenopus embryonic kidney with proximal tubules in light blue, distal tubules in blue, and
connecting tubules in dark blue. Scale bar represents 100 µm.
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To assess whether Dyrk1a depletion affects kidney function, an assay was
performed evaluating edema formation (172). Edema can be caused by a disruption
in the kidneys’ ability to excrete excess fluid, but it can also be caused by heart or
liver failure. Both the heart and liver arise from dorsal cells in Xenopus
(Xenbase.org). To prevent knockdown in these tissues, embryos were injected with
Dyrk1a MO or standard MO in both ventral cells at the four-cell stage to affect both
kidneys. Embryos injected with the Dyrk1a MO suffered from edema and abnormal
kidneys, characterized by swelling in the chest cavity due to fluid retention (Figure
12I) while embryos injected with the standard MO did not (Figure 12H). Though the
ventral cells do not give rise to the heart or liver, which also can lead to edema if
perturbed, I still assessed the heart of Xenopus embryos, as DYRK1A syndrome
patients also have heart anomalies (145, 180). Embryos injected with Dyrk1a MO
have normal heart morphology and similar cardiac beating as the standard MO
control embryos (Figure 15). These techniques suggest that the edema is due to
loss of kidney function in Xenopus. Taken together, these data support a role for
DYRK1A in pronephric development and strongly suggest that the DYRK1AR205* and
DYRK1AL245R variants are responsible for the kidney anomalies observed in these
patients.

3.26 Other Findings
In addition to understanding how Dyrk1a loss alters the kidney, I have
preliminary data suggesting that overexpression also leads to kidney abnormalities.
First, I found that overexpressing 50 pg of Xenopus dyrk1a mRNA lead to dilated
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Figure 15. Injecting Both Ventral Cells of 4-Cell Embryos Does Not Affect Heart
Morphology or Cardiac Beating.
(B) Embryos injected with 10 ng of Dyrk1a MO in both ventral cells at the 4-cell stage do not
affect heart morphology compared to the (A) standard MO control, as seen by the black
dashed lines. White dashed line indicates edema formation in the Dyrk1a MO tadpole.
Additionally, Dyrk1a MO injected embryos show cardiac beating
(https://www.youtube.com/watch?v=EwE2uVfql7I) similar to the standard MO control
embryos (https://www.youtube.com/watch?v=vbU5hhVbkhw ).
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and/or cyst-like formation in the kidney in several embryos (Figure 16). Cyst
formation, dilated tubules, and ectopic tubule formation can also be seen with
Dyrk1a MO knockdown in the kidneys. Though this experiment needs to be
repeated, I have overexpressed 50 pg of human DYRK1A mRNA and found that the
Xenopus kidney looks slightly different compared to age-matched controls (Figure
13). Though there is no significant difference for overall kidney morphology, there is
loss of convolution in the distal tubules and shorter proximal tubules which is
indicative of underdevelopment. Though not seen often, I also noted several
embryos had tubule dilation as seen with overexpressing Xenopus dyrk1a mRNA. In
Down syndrome patients who have an extra copy of DYRK1A, renal cysts and
tubule dilation have been recorded (192, 193). Given that these specific kidney
phenotypes occur with both Dyrk1a loss and overexpression this suggests
dysregulation of Dyrk1a needs to be tightly regulated. I also have looked at other
tissues outside of the kidney that were interesting to me where dyrk1a was
expressed.
Through discussions with peers who have worked with DYRK1A I chose to
see if Dyrk1a loss would alter craniofacial structures or neural crest cell migration in
Xenopus. I have noticed that loss of Dyrk1a alters melanocytes, which are neural
crest cell-derived pigment cells. Craniofacial structures likewise arise from the neural
crest cells. I utilized a transgenic line where a CMV promoter drives RFP expression
in the nucleus called Xla.Tg(CMV:hist2h2be-RFP)Ueno. First, I Injected single cell
Xenopus embryos with 10 ng of Dyrk1a MO and performed neural crest explants on
stage 17 embryos and put explants on a glass slip in fibronectin. I then did live
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Figure 16. Xenopus dyrk1a Overexpression Leads to Kidney Abnormalities.
(A) dyrk1a overexpression in the kidney can lead to cyst-like formation or (B) dilated tubules.
Both phenotypes are depicted by white arrows. Dilated tubules are also seen with human
DYRK1A mRNA overexpression.
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imaging to track cell migration of the neural crest explants. I used Imaris software to
track nuclei from these live imaging videos in order to assess cell migration (Figure
17). The nuclei tracking demonstrates that the wild-type explant cells appear to work
together to migrate a certain direction whereas the Dyrk1a MO injected explant fails
to move cohesively in a specific direction. Instead, the cells seem to go in circles,
seemingly lost as to which direction they should migrate. This suggests that Dyrk1a
may be important for proper cell migration in neural crest cells. To further
understand if Dyrk1a may be affecting neural crest cells, I next looked at craniofacial
structures.
I injected 10 ng of Dyrk1a or standard MO into both dorsal cells of four cell
embryos which target the neural crest. I found the embryos injected with the
standard MO appeared normal, but embryos injected with the Dyrk1a MO had a
range of facial anomalies including coloboma (hole in the iris), narrow head, and loss
of eyes (Figure 18). It is also apparent in the Dyrk1a MO injected embryos that the
melanocytes are lost or have defects with migration given their haphazard
localization compared to control embryos (Figure 18).
Though most of these experiments are outside of the scope of this
dissertation, they demonstrate the Xenopus serves as a promising model not only of
the kidney, but also as a model for other tissues that Dyrk1a may affect. I have
shown preliminary data that Dyrk1a loss disrupts neural crest cells through
disrupting migration, as well as resulting in abnormalities in melanocytes and
craniofacial structures. This opens up a potential new project for the lab to pursue.
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Figure 17. Nuclei Tracking of Neural Crest Explants Demonstrates That Dyrk1a Loss
Leads to Loss of Coordinated Cell Migration.
I injected single cell Xenopus embryos with 10 ng of Dyrk1a MO along with a GFP cytosolic
lineage tracer and performed neural crest explants on stage 17 embryos. Explants were
done in the transgenic line Xla.Tg(CMV:hist2h2be-RFP)Ueno where RFP is a reporter for
Histone 2B expression in the nucleus. Uninjected Xla.Tg(CMV:hist2h2be-RFP)Ueno embryos
served as a control. I utilized live imaging to track cell migration of the neural crest explants.
In order to assess cell migration I used Imaris software to track nuclei from the videos made
from live imaging. Time is tracked by color where the blue coloring of the lines indicates
where the cells first started and the green to red coloring demonstrates where they end.
Nuclei tracking demonstrates that the wild type explant cells appear to work together to
migrate a certain direction https://youtu.be/vYa‐eIlvo1A , whereas the Dyrk1a MO injected
explant fails to move cohesively in a specific direction https://youtu.be/z_vWq5jOQo0.
Explants were placed on fibronectin during live imaging.
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Figure 18. Dyrk1a Loss in Neural Crest Cells Leads to Craniofacial Anomalies.
I injected 4 cell Xenopus embryos with 10 ng of standard or Dyrk1a MO in both dorsal cells
which target the neural crest cells. (A) Stage 45 Embryos injected with the Standard MO
appeared phenotypically normal whereas stage 47 embryos injected with the Dyrk1a MO
suffered from (B) dysmorphic facial features, loss of eye structures, and (C) coloboma
(smearing-like appearance of the eye). (A) Dashed line demonstrates the normal pattern
distribution of melanocytes on the head whereas (B-C) arrows point to abnormal
melanocytes, which are also neural crest cell-derived. Staging was assessed by spiraling of
the gastrointestinal tract.
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3.3. Discussion
Recent discoveries demonstrate that de novo pathogenic variants in DYRK1A
cause a syndromic form of intellectual disability (OMIM 614104). The findings in the
current study indicate that CAKUT/genital defects should be included as features
associated with this syndrome. CAKUT consist of a heterogeneous clinical
spectrum, and how CAKUT arise is largely unknown. Thus, it is important to identify
all genes and causal variants involved (194). Strong genetic causality of monogenic
disease only accounts for 14%of CAKUT cases (55), and polygenic causes are
speculated to occur but are largely unknown (195). Next-generation sequencing,
specifically exome sequencing, has improved the discovery of novel causative
genes that are important in genitourinary development (196–198). Here, we report
on a novel genetic contribution of DYRK1A to CAKUT/genital defects. We identified
17 unique variants in DYRK1A from clinical exome sequencing in 19 unrelated
individuals. As summarized in Table 2, microcephaly, intellectual disability,
developmental delay, and seizures are some of the more common features of this
syndrome.
Eleven of fifteen (73% of those with available data) individuals in this study
(Table 3) have CAKUT/genital defects, with 36% having renal anomalies, in addition
to other organ involvement. While renal anomalies have been reported previously
(181), broadly based phenotyping for CAKUT was not performed in previous studies.
Seven of the DYRK1A variants identified in our study were novel as they were
absent in ClinVar as well as the gnomAD and ExAC databases. Per inclusion
criteria, most of DYRK1A variants were de novo and included truncating variants.

76

This suggests a loss-of-function mechanism for variants causing this syndrome,
which further supports the findings of another group who proposed reduced kinase
function as the cause (183).
In addition, we determined that dyrk1a is expressed in the developing
Xenopus kidney and found that Dyrk1a knockdown results in abnormal tubules or
complete loss of the kidney. This phenotype could be partially rescued by human
DYRK1A mRNA. However, a nonsense (R205*) and a missense (L245R) variants
failed to rescue the phenotype, indicating that loss-of-function variants in this gene
are likely causative for the observed phenotype in some patients. This also suggests
that DYRK1A's kinase domain may be important for kidney development.
Furthermore, Dyrk1a MO was injected into both ventral cells at the four-cell stage to
affect both kidneys, which resulted in edema suggesting that Dyrk1a is important for
both kidney development and function. Although Xenopus is an established model of
nephron development, it has not been commonly used to study genital defects.
However, our findings related to pronephric development are likely relevant to the
mammalian urogenital tract, given the dependence of the formation of the male and
female urogenital tract upon the nephric duct and the pronephros.
Though it was not explored in this study, DYRK1A overexpression in some
Xenopus embryos led to underdeveloped kidneys. This suggests DYRK1A
overexpression may also affect kidney development. Interestingly, several studies
estimate that the incidence of renal and urogenital anomalies in Down syndrome
patients ranges from 3.5–21.4% (192, 193) and my preliminary data shows that both
of these occur with overexpression of Xenopus dyrk1a. Given that Down syndrome
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has a triplication of DYRK1A, this gene may affect urogenital and kidney
development when its normal dosage is altered. However, I also see both
phenotypes, as well as ectopic tubule formation when Dyrk1a is lost, suggesting that
it must be tightly regulated to achieve proper nephrogenesis. Furthermore, I
demonstrate preliminary data that Dyrk1a loss results in abnormal neural crest cell
migration, craniofacial anomalies, and altered melanocyte localization. This suggests
that Dyrk1a also may be important for proper neural crest cell migration given that it
results in multiple abnormal cell/tissue types that all arise from neural crest cells.
One limitation of this study is that we were not able to obtain genitourinary
information from all patients. Future plans for research include identification and
studying the phenotype and underlying variants in a larger number of affected
families. Furthermore, signaling pathways involved in DYRK1A-related
CAKUT/genital defects should be investigated. DYRK1A has been shown to affect
Notch signaling and calcium signaling (150) which are both important for kidney
development (199, 200). Additionally, several papers have implicated DYRK1A in
canonical Wnt signaling (148, 201).
In summary, based on the data we present in this study, the phenotype of
DYRK1A-related intellectual disability syndrome is now expanded to include
CAKUT/genital defects. Our data suggests that DYRK1A may affect kidney
development through its catalytic activity, though this should be examined further.
We empirically recommend that individuals with DYRK1A syndrome undergo a renal
ultrasound and a thorough genital physical exam, which can improve patient quality
of life.
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CHAPTER 4: DYRK1A AND WNT SIGNALING IN KIDNEY DEVELOPMENT

4.1 Introduction
It is well-established that canonical Wnt signaling is an important player in
kidney organogenesis (41–47). It is necessary for nephron induction in mice (45),
and is essential for renal branching morphogenesis, (46) as well as maintaining the
nephron progenitor pool (47). Canonical Wnt signaling is also involved in the
development of the Xenopus pronephros (43, 44). Overexpression or loss of
canonical Wnt signaling in Xenopus leads to loss of kidney tubules (44) whereas
overexpression of β-catenin in the mouse kidney leads to severe polycystic lesions
that affect the entire nephron (52). These studies suggest that endogenous levels
must be tightly maintained to achieve proper nephrogenesis, though its regulation
during nephrogenesis is not completely understood. It could be that DYRK1A acts as
a regulator for Wnt signaling during nephrogenesis.
Though canonical Wnt signaling is heavily studied, the precise cause of
GSK3β inhibition to stabilize β-catenin is still unknown and speculated by several
different models (202). DYRK1A has been found to phosphorylate GSK3β at residue
T356, which inhibits its activity and leading to increased β-catenin levels in vitro and
in white adipose tissue in mice (201). Although Xenopus does not share the
conserved T356 residue, it has at least two possible DYRK1A consensus sequences
that could be phosphorylated to inhibit GSK3β, including T309. Additionally,
DYRK1A could modify the Wnt pathway through other Wnt components. It has been
found that DYRK1A interacts with both Dickkopf-related protein 3 (DKK3) and DVL1
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endogenously by co-immunoprecipitation in HEK293 cells (148). Furthermore, when
both DYRK1A and DVL1 are co-transfected in SH-SY5Y neuronal cells transfected
with TOPflash Wnt reporter it increases Wnt activity as seen by an increase in
luciferase (148). In addition, DKK3 has been found to be decreased in Down
syndrome patient samples while it is increased in the Down syndrome Tc1 mouse
model (148). Given that the previous studies focused on understanding DYRK1A’s
effect in cell culture and down-syndrome mouse models, we sought to better
understand how DYRK1A modified the Wnt pathway during normal embryogenesis,
specifically nephrogenesis. Because Wnt signaling plays a vital role in normal kidney
development, it is conceivable that DYRK1A alters β-catenin levels to fine tune Wnt
activity during nephrogenesis.

4.2 RESULTS
4.21 Dyrk1a Perturbation Alters β-Catenin Levels
The canonical Wnt pathway is important for many developmental processes,
including dorsoventral axis specification with the highest levels of canonical Wnt
signaling leading to head formation (203) and lowest levels leading to body trunk
formation. Though I did not see abnormalities when overexpressing dyrk1a in the
dorsoventral axis (data not shown), it was previously shown that co-expressing
dyrk1a with a subphenotypic dose of β-catenin mRNA in Xenopus embryos
enhanced duplicate axis formation, while kinase dead dyrk1a had no such effect
(171). Similarly, reduced β-catenin results in ventralization in Xenopus embryos
(203), and I demonstrate that the same phenotype occurs when Dyrk1a MO is
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injected into dorsal cells which give rise to the head (Figure 19). These data suggest
that Dyrk1a is altering the canonical Wnt pathway, potentially through β-catenin
levels. To test this, I injected single cell embryos with either 40 ng of Dyrk1a MO, 1
ng dyrk1a, or 1 ng β-gal mRNA. I found that loss of Dyrk1a leads to lowered total βcatenin protein levels (Figure 20, lane 5). This result was somewhat unexpected, as
levels of free β-catenin are generally low. It could be that Dyrk1a is somehow
affecting the β-catenin pools that are bound to adherens junctions, though my
dorsoventral data suggests it is affecting the signaling pool of β-catenin. In order to
test this, I utilized an active β-catenin antibody to examine if the signaling pool of βcatenin is being altered.
The active β-catenin antibody, which will only recognize the stable form of βcatenin that is not phosphorylated on residues Ser33/37/Thr41, recognizes what is
also known as the transcriptional pool of β-catenin. In addition, to increase
specificity, I used our transgenic Xenopus line, Tg(pbin7LEF-GFP) canonical Wnt
reporter frogs (204). This line contains a construct consisting of a synthetic
promoter, seven copies of an optimal binding sequence for LEF/TCF factors, and a
minimal TATA box in front of a GFP reporter gene (https://www.mbl.edu/xenopus). I
injected single cell embryos with either 20 or 40 ng of standard MO as a negative
control or 20 or 40 ng Dyrk1a MO then examined active β-catenin and GFP
expression by Western blot (Figure 21). The results demonstrated that Dyrk1a loss
also reduces the signaling pool of β-catenin. Additionally, even though the active βcatenin antibody shows loss of expression only when 40 ng of the Dyrk1a MO is
injected, the GFP antibody demonstrates that GFP expression is also lost with only
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Figure 19. Ventralization Results When Dyrk1a MO is Injected into the Dorsal Cells.
I injected 10 ng of either Dyrk1a or standard MO into both dorsal cells of four-cell embryos.
(A) Standard MO injection does not result in ventralization, but (B) Dyrk1a MO injection
does. (C) The graph demonstrates almost 40% of Dyrk1a MO injected embryos have a
ventralization phenotype whereas no embryos in the control group do. Experiments were
repeated three times with error bars representing standard error. The total number of
Xenopus embryos are as follows: Standard MO: 78, Dyrk1a MO: 43.
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Figure 20. Knockdown of Dyrk1a Results in Reduced Total β-Catenin Protein.
(A) Compared to the uninjected (lane 1) and Standard MO (lane 4) controls, total β-catenin
protein is reduced (lane 5) upon Dyrk1a MO knockdown in neurula stage 16-17 embryos.
(B) Adjusted densities were done for (B) total β-catenin expression where expression was
normalized against GAPDH which served as a loading control. Overexpressing dyrk1a (lane
3) does not increase β-catenin compared to control (lane 2). β-catenin runs at 95 kDa, while
GAPDH runs at 37 kDa. Lysates where lysed open with TX Lysis buffer.
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Figure 21. Knockdown of Dyrk1a Results in Reduced Active β-Catenin Protein.
I injected the Tg(pbin7LEF-GFP) canonical Wnt reporter single cell embryos with either 20
ng or 40 ng of Dyrk1a MO or Standard MO as a negative control. (A) Compared to the β-gal
(lane 1) and Standard MO (lane 2 and 4) controls, active β-catenin protein is reduced (lane
5) upon Dyrk1a MO knockdown in early tadpole stage 32 embryos. Although not seen with
active β-catenin (top row), using 20 ng of Dyrk1a MO reduces GFP protein expression.
Adjusted Densities were done for (B) active β-catenin expression and (C) GFP expression
where expression was normalized against GAPDH which served as a loading control. Active
β-catenin runs at 95 kDa, while GFP runs at 40 kDa, and GAPDH runs at 37 kDa. GAPDH
was reblotted after GFP. All injected embryos were selected based on RFP lineage tracer
expression. Uninjected embryos were selected based on GFP expression. A potential bias
in selecting GFP embryos that were not too dim nor too bright may account for lower GFP
expression in uninjected controls. (B) Standard error is shown for uninjected and 40 ng of
either Standard or Dyrk1a MO, as I had 2 replicates for them. I only had 1 replicate for 20 ng
lysates and therefore they do not have standard error included.
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20 ng of Dyrk1a MO. This suggests that the quantification using the GFP antibody is
more sensitive to alterations made to the transcriptional pool β-catenin. This is
somewhat expected given that it detects only the β-catenin that has bound to
TCF/LEF binding sites on the transgenic reporter sequence.
Next, I sought to understand if overexpression of dyrk1a would lead to
alterations in active β-catenin. I injected the Tg(pbin7LEF-GFP) canonical Wnt
reporter single cell embryos with either 250 pg or 500 pg of dyrk1a or β-gal mRNA
as a negative control. My initial studies used TX lysis buffer to dissociate the
embryos for lysate use, but upon seeing no change in active β-catenin or GFP
expression (data not shown) I changed to a buffer with SDS. This harsh detergent
followed by sonication allows for the lysis of the nucleus, where most of the active βcatenin would likely be found. With this detergent I did see a change in GFP, but not
active β-catenin expression by Western blot (Figure 22). Given that my previous
results demonstrate the quantification of bound β-catenin using the GFP antibody is
more sensitive, it is likely because discreet changes in the signaling pool of βcatenin cannot be detected by a typical active β-catenin antibody.
Because minute levels of β-catenin can reach the nucleus and activate Wnt
target genes, in some cases differing methods should be utilized even if changes are
not seen with a commercial active β-catenin antibody. Dyrk1a may make discreet
changes to the Wnt pathway which can still have an effect downstream but may be
difficult to detect. I ran into this problem when trying to see if overexpression of
dyrk1a would lead to increased GFP expression in the kidney of Wnt reporter frogs.
Targeted kidney injections with dyrk1a overexpression did not show a reliable
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amount of increased GFP expression compared to negative controls. I also tried to
stimulate canonical Wnt signaling in dyrk1a injected embryos by placing the
embryos in GSK inhibitor Lithium Chloride (LiCl). First I placed uninjected Wnt
reporter embryos at either stage 18 or stage 25 in 25, 35, 45, 55, or 65 mM of LiCl
and left them in the molecule overnight. For past lab members 25 mM of LiCl worked
to stimulate GFP expression in the kidney whereas 100 mM killed all embryos and
lower doses showed no expression. However, I could not find a dose where
embryos were healthy enough to grow up to the stage I needed (stage 35). I used
the lowest dose of 25mM, to stimulate Wnt signaling in embryos that had been
injected with dyrk1a or β-gal mRNA. Unfortunately, it did not elicit a reliable GFP
expression in the kidney, even when immunostained with GFP. The embryos were
also extremely sick from being submitted to both LiCl and microinjections. However,
I did find an unexpected result when injecting Wnt reporter frogs with the Dyrk1a
MO.
I injected a single V2 blastomere in 8-cell embryos with either standard or
Dyrk1a MO. Instead of seeing a reduction in expression, as expected, I saw multiple
embryos with increased GFP expression (Figure 23B and D) at stages 35 and 40. I
also have preliminary data demonstrating that injecting single cell embryos with a
lower dose of Dyrk1a MO seems to increase total and active β-catenin expression
by Western blot instead of reducing it (Figure 23E-H). This may suggest that
DYRK1A alters canonical Wnt signaling differentially in specific circumstances.
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Figure 22. GFP Expression is Increased with dyrk1a Overexpression Upon Lysis of
the Nucleus.
I injected the Tg(pbin7LEF-GFP) canonical Wnt reporter single cell embryos with either 250
pg of 500 pg of dyrk1a or β-gal mRNA as a negative control. I used a buffer with SDS which
lyses the nucleus open, where most of the active β-catenin would likely be found. (A)
Adjusted densities were done for (B) GFP expression where expression was normalized
against Actin which served as the loading control. GFP expression increases, but active βcatenin expression remained unaltered. This demonstrates that dyrk1a overexpression
increases the transcriptional pool of β‐catenin as seen through GFP.
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Figure 23. Inhibiting Dyrk1a at a Lower Dose Increases Wnt Signaling.
Dyrk1a knocked down in Wnt reporter line. (A-B) When Dyrk1a is knocked down in targeted
kidney injections, a dose of 10 ng leads to (B) increased Wnt expression at stage 35 and (D)
stage 40 embryos as seen by GFP immunostaining. White box is over the proximal and
early distal kidney tubules. (E-F) Dyrk1a loss leads to increase in total β-catenin compared
to loss of β-catenin expression seen with 40 ng of Dyrk1a MO. (G-H) Similar results are
seen with active β-catenin expression. Note in (G-H) active β-catenin expression would be
similar to (F) if the bubble was not present in the blot. GAPDH was used as a loading
control.
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4.3 Discussion
Though there are multiple pathways that DYRK1A may be acting through to
influence kidney development, my data suggests that it may be acting through the
canonical Wnt pathway. This does not exclude the possibility that it also affects other
pathways during nephrogenesis, which will need to be illuminated through additional
studies. In mice, DYRK1A was shown to phosphorylate and inhibit GSK3β on the
residue T356. Although Xenopus does not share the conserved T356 residue, it has
at least two possible DYRK1A consensus sequences that could be phosphorylated
to inhibit GSK3β. My data does not directly implicate that Dyrk1a acts through the
canonical Wnt pathway by inhibiting GSK3β, but it clearly demonstrates β-catenin is
being altered in whole embryos. My data shows that loss of Dyrk1a leads to reduced
β-catenin expression by Western blot and leads to ventralization of embryos when
Dyrk1a is specifically reduced in the dorsal cells. I also demonstrate that active βcatenin and GFP expression indicative of Wnt signaling are reduced upon Dyrk1a
loss and that GFP expression is increased upon dyrk1a overexpression by Western
blot. In addition, I also show with preliminary data that a lower dose of 10 ng of
Dyrk1a seemed to increase both active and total β-catenin by Western blot (Figure
23E-H) as well as increased GFP expression for targeted kidney microinjections
(Figure 23A-D). This suggests that Dyrk1a’s interaction with the canonical Wnt
pathway may be complex and that in different circumstances or in different doses, it
may elicit an alternate outcome of Wnt signaling. Though this is outside of the scope
of this dissertation, it is likely that DYRK1A is affecting more than just the canonical
Wnt pathway.
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Because DYRK1A also alters the cytoskeleton and the calcium pathway it
may be that it influences the three main Wnt pathways in kidney development,
though most likely not at the same time, if at all: the canonical and non-canonical
PCP pathways appear to antagonize each other which prevents both from being
active in the same cell at the same time (205). DYRK1A may also affect multiple Wnt
pathways in a linear fashion, as it has been found that the calcium/NFAT pathway
acts downstream of canonical Wnt ligand Wnt4 (206). It is tempting to speculate that
DYRK1A could affect the various Wnt pathways during kidney development or
embryogenesis, and even act as a switch between them, though there is no data to
support this. DYRK1A has also been shown to regulate another catenin, p120 (158).
Dyrk1a has been found to directly regulate p120 (158), which is another
catenin that both transcriptionally regulates Wnt genes and associates with Ecadherin to form adherens junctions. In addition, p120 also regulates small GTPases
RhoA and Rac1 (158). Though the study showed that it directly increased the
signaling pool of p120 and suggested it may not affect p120 in junctions, no
experiments were shown to dispute this. It has been found that siRNA knockdown of
p120 in SW48 cells resulted in dose-dependent loss of E-cadherin and complete
loss of cell-cell adhesion (207). Thus, it is possible that loss of p120 could lead to
loss of a junction, including loss of β-catenin. Given that Dyrk1a loss altered both
active and total β-catenin levels, it may be affecting both the transcriptional and nontranscriptional pools of β-catenin.
Although most of my data suggests that Dyrk1a positively regulates the
canonical Wnt pathway, I have some experiments that suggest otherwise. I have
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preliminary data both by Western blot and by immunofluorescence that suggests
loss of lower levels of Dyrk1a lead to increased β-catenin expression (Figure 23).
Previous literature demonstrates that increased DYRK1A expression in the Tc1
mouse leads to increased DKK3 expression (148). It may be that loss of DYRK1A
could lead to lower levels of Wnt antagonist DKK3, which may lead to increased
canonical Wnt signaling in specific circumstances. Given that others and I have seen
both inhibitory and activating DYRK1A activity on the canonical Wnt pathway (148),
it is likely that these interactions are tissue-dependent, and on other factors including
age of the organism, where interactions during development may be vastly different
that those that occur in specific disease state, as well as if changes made to
DYRK1A are large or discreet.
Although canonical Wnt signaling is essential for kidney development (39–45)
its regulation during this time is not completely understood. My data suggests that
Dyrk1a alters β-catenin and acts through the canonical Wnt pathway. I have shown
that this occurs in vivo in whole Xenopus embryos in stages when nephrogenesis is
occurring. And though most of my experiments only implicated Dyrk1a in acting
through the canonical Wnt pathway during embryogenesis, I do have preliminary
data suggesting it is also changing Wnt signaling during kidney development (Figure
23). It is possible that this interaction also occurs in mammals, as Wnt signaling is
also essential for embryogenesis and kidney development, but further studies will
have to decipher this. Though I was not able to ascertain if Dyrk1a is altering βcatenin through GSK3β inhibition, changes to β-catenin may explain the observed
Dyrk1a embryo and kidney phenotypes.
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CHAPTER 5: CONCLUSIONS, DISCUSSION, AND FUTURE DIRECTIONS

5.1 Conclusions and Discussion
The kidney is an important excretory organ that eliminates nitrogenous waste,
balances the electrolyte levels in the body, controls blood pressure, stimulates red
blood cell production, and maintains the density of our bones (2). The structural and
functional unit of the kidney, the nephron, filters the blood to regulate water and
various soluble substances and reabsorbs what is needed and removes the rest as
urine (1). The nephron’s function is vital for homeostasis of both blood pressure and
volume, acid-base balance, and plasma osmolarity (1). Given the important and vast
functions of the kidneys in the human body, it is vital to understand how anomalies
arise during development. Xenopus laevis contain one functional pronephric
nephron on either side of their body, which serves as a simplified model for
mammalian meso- and metanephric nephron development (Figure 2). This simplified
model can help us understand how CAKUT may arise.
Congenital anomalies of the kidney and urinary tract (CAKUT) are a leading
cause of chronic kidney disease in children (53). CAKUT can appear as an isolated
feature or be multi-syndromic with extra-renal clinical manifestations (53). Though
kidney organogenesis is well-studied, gaps in understanding still remain. This failure
to fully grasp how the kidney develops translates into low cure rates for many of the
genetic disorders that cause kidney disease. Only 14% of known CAKUT cases
have strong genetic causality for monogenic disease (55). Polygenic disease is likely
to occur but it is largely unknown how frequently (195). Uncovering more causative
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genes will aid in our understanding of how the kidney develops and what processes
lead to abnormal development. This dissertation reveals a new gene important for
nephrogenesis called DYRK1A.
Unpublished clinical findings suggested that patients who suffer from
DYRK1A haploinsufficiency, known as DYRK1A intellectual disability syndrome, had
a higher prevalence of CAKUT, but it was not understood why. This dissertation
demonstrates that DYRK1A mutations are likely causative in CAKUT cases seen in
DYRK1A-syndrome patients through several key experiments. I use Xenopus as a
model to show that dyrk1a is expressed in the pronephric kidney and dyrk1a loss
leads to abnormal kidney formation. Additionally, I demonstrate that knockdown of
Dyrk1a in both kidneys leads to edema formation, likely because kidney function has
been lost. Furthermore, I show this kidney phenotype can be rescued by co-injecting
human wild-type DYRK1A mRNA. However, nonsense (R205*) and missense
(L245R) patient mutant mRNA fail to rescue the phenotype.
In our data set, neither intellectual disability nor CAKUT/genital defects had a
predictable severity, though we did not utilize biochemical assays to explore this
possibility thoroughly. Several studies have demonstrated generally that DYRK1A
mutations which occur more C-terminally retain more kinase function (145, 183,
185). For instance, the A498fs mutation loses 50% of kinase activity (185) and has
mild intellectual disability (145). Given that the mutations we modeled result in
complete loss of kinase activity (185), it may be that DYRK1A’s role in
nephrogenesis is dependent on it as intellectual disability seems to be.
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Specific mutations can also retain partial kinase activity or even lead to
hyperactivity (185). The DYRK1A A195T mutation leads to a 2-fold increase in
kinase activity but still leads to mild intellectual disability and other DYRK1Asyndrome characteristic features such as language impairment and global
developmental delay (208). However, these features can also be found in Down
syndrome patients, which have an additional copy of DYRK1A (209). Therefore, the
resulting clinical features may be a result of DYRK1A hyperactivation. Though we
had no patients in this cohort with the A195T mutation, it has been shown that some
Down syndrome patients who have an extra copy of DYRK1A have kidney cysts and
tubule dilation (192, 193). In fact, I demonstrate that DYRK1A overexpression may
also affect kidney development through loss of tubule convolution indicative if
developmental delay (Figure 13). Additionally, I have preliminary data showing that
overexpression of dyrk1a leads to cyst-like formation in the Xenopus kidney, though
further replications need to be performed to validate this (Figure 16). Though
DYRK1A dose is an important factor in clinical urogenital manifestations, it is still
unknown which pathway or pathways DYRK1A is acting through.
In this dissertation, I attempted to uncover if Dyrk1a acts through the
canonical Wnt pathway in Xenopus kidney development, though most of my efforts
can only confidently demonstrate that it is acting through Wnt signaling during
embryogenesis. It is possible that Dyrk1a is altering the Wnt pathway through
GSK3β as DYRK1A has been found to phosphorylate GSK3β at residue T356,
which inhibits its activity (201). Xenopus does not share the conserved T356
residue, but it has at least two possible Dyrk1a consensus sequences that could be
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phosphorylated to inhibit GSK3β, including T309. Though I did not do experiments to
implicate GSK3β I found that changes to Dyrk1a alter β-catenin. I show that loss of
Dyrk1a leads to lowered total and active β-catenin expression by Western blot, as
well as GFP loss in a Wnt reporter Xenopus line. Additionally, I found that
overexpressing dyrk1a in the Wnt reporter frogs leads to increased GFP expression
which suggests Dyrk1a is increasing canonical Wnt signaling during embryogenesis.
Furthermore, I demonstrate ventralization of embryos when Dyrk1a MO is injected
into the dorsal cells, similar to a loss of Wnt signaling in dorsal cells. I also show
preliminary data suggesting that Dyrk1a loss leads to increased Wnt signaling in the
Xenopus kidney, though more replicates will have to be done to verify this
contradictory result. I only scratched the surface in understanding how Dyrk1a could
be acting through the Wnt pathway. Future work should focus in the exact
mechanism of how this occurs in the context of kidney development, as it may be a
potential CAKUT therapeutic avenue.

5.11 DYRK1A’s Known Interactions with Pathways Involved in Kidney
Development
Given that this is the first time DYRK1A has been found to contribute to
kidney development it is not known what pathway(s) it is acting through. However,
Dyrk1a does interact with pathways in other tissues that have a known function
during kidney development. I will briefly discuss a few pathways that DYRK1A may
be acting through to exert its function on kidney development and why the Wnt
pathway became an attractive candidate.
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There are many different pathways that play a role in kidney development.
Some key pathways include FGF, GDNF, Sonic Hedge Hog (SHH), Notch, Calcium
signaling, PCP, and canonical Wnt signaling pathways (6, 210). In order to
understand which pathways DYRK1A may be acting through, it is important to
understand when these pathways contribute to kidney development and how
DYRK1A has been shown to modulate them in other tissues.
The GNDF/Ret pathway plays a role early in kidney development by in
inducing ureteric bud outgrowth and subsequent branching (2). FGF signaling
likewise occurs early and is critical for ureteric bud and metanephric mesenchyme
formation (211). It is thought that Sprouty2, a known antagonist of FGF signaling,
may coordinate Wnt11/Gdnf/Fgf7 during kidney development (212). DYRK1A has
been found to positively regulate FGF through inhibiting Sprouty2 in the mouse
central nervous system (213). Given that GDNF, FGF, and Sprouty2 signaling occur
so early in kidney development and that loss of it leads to complete kidney or
nephron loss (211, 212, 214), it is unlikely that DYRK1A is acting through either
pathway via Sprouty2. However, DYRK1A has been shown to modulate Wnt11
through a direct interaction with p120 during Xenopus gastrulation (158). In addition,
Wnt11 seems to have a role later in kidney development, specifically coordinating
the development of kidney tubules, and Wnt11 loss leads to abnormal tubule
formation (215). However, other Wnts such as Wnt9 and Wnt4 occur much earlier to
induce renal vesicle formation and lead to more severe kidney loss (6, 41, 43, 206,
216). DYRK1A has been found to interact with downstream components of the Wnt
pathway including GSK3 in mouse white adipose tissue (201) and DVL1 and DKK3
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in the mouse hippocampus and in HEK293 cells (217) This leaves Wnt signaling as
a potential DYRK1A pathway candidate.
SHH also has a known role in regulating proliferation and differentiation of the
metanephric mesenchyme in mice (218). In the mouse brain DYRK1A has been
found to positively regulate SHH through GLI3 and also can dampen SHH which is
thought to be mediated through DYRK1A’s negative regulation of actin dynamics
(149). Though DYRK1A interacts with the SHH pathway, Loss of SHH mostly leads
to ureter anomalies in mouse models, which is not seen in DYRK1A syndrome
patients. However, pursuing how DYRK1A changes actin dynamics may implicate
the PCP Wnt pathway.
DYRK1A has been found to negatively regulate F-actin in the mouse brain
through inhibiting ABLIM proteins which stabilize actin (149). In addition, DYRK1A
interacts with DVL1 to increase canonical Wnt signaling (217). It is thought that
differential recruitment of DVL to the membrane acts as a switch between PCP and
canonical Wnt pathways (219). In addition, mutations in different PCP genes in mice
leads to duplicated, hypodysplastic, and/or misshapen kidneys. I have seen both
dilated tubules and ectopic tubule buds with Dyrk1a loss and overexpression in
Xenopus kidneys. It may be possible that these abnormalities are a result of
changed actin dynamics or the PCP pathway, as PCP disruptions can lead to tubule
dilation and duplicate kidneys (220). When Dyrk1a is lost these branches could arise
from an increase in F-actin which increases cell movements. In addition, the
resulting phenotypes could occur with activation of the PCP pathway which could
inhibit the canonical Wnt pathway. Furthermore, if DYRK1A levels somehow acts as
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a switch between Wnt pathways the phenotypes that arise from DYRK1A’s altered
state could be acting through DVL1. Therefore, the non-canonical PCP pathway may
also be a viable candidate pathway.
Another pathway that DYRK1A interacts with is Notch signaling where it has
been found to attenuate Notch signaling in the mouse brain (221). Notch2 plays a
role in proximal nephron fates and loss of Notch2 in the metanephric mesenchyme
leads to loss of glomeruli and proximal tubules (222). Loss of proximal tubules is
seen in the Xenopus kidney, however, loss of DYRK1A would increase Notch
signaling which has been shown to lead to premature tubule differentiation and
dilated tubules (223) and thus is an unlikely pathway for DYRK1A to act through.
However, the calcium signaling pathway may be a promising candidate.
DYRK1A has been found to regulate calcium signaling by maintaining inactive
NFAT in neuronal cells (146) as well as enhancing RCAN1s ability to inhibit
calcineurin in neuronal cell line PC12 (224). In addition, in zebrafish loss of dyrk1a
led to increased calcium signaling which caused hemorrhaging in the brain (150).
The Calcium/Wnt pathway has been implicated in nephrogenesis by treating primary
metanephric mesenchymal cells with Wnt4. This treatment caused significant Ca2+
influx leading to tubule formation which could be blocked in presence of Ca2+
chelator (199). DYRK1A has been found to inhibit calcium signaling in multiple tissue
types and loss of calcium signaling leads to widened tubules in Xenopus. Though
the phenotype for overexpression of calcium signaling is not known, it could be how
DYRK1A influences kidney development. It is known that the calcium/NFAT pathway
acts downstream of canonical Wnt ligand Wnt4 (206) and that calcium signaling
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inhibits canonical Wnt signaling which leads to abnormal kidney development.
Therefore, it may act by throwing off the balance between the different Wnt
pathways. The canonical Wnt pathway became my focus because initial
experiments with Dyrk1a such as the dorsoventral experiment implicated canonical
signaling. However, given that DYRK1A interacts with DVL1, which has been called
the hub of the three main Wnt pathways, it is plausible that disruption of DYRK1A
may lead to disruption of the synergy between Wnt pathways (Figure 24).

5.12 Overall Conclusions
Congenital anomalies of the kidney and urinary tract are a leading cause of
pediatric kidney failure and result from defects in morphogenesis. This work
highlights a novel gene implicated in CAKUT known as DYRK1A. By using Xenopus
laevis as a model I determine that Dyrk1a is essential for kidney development, as
well as the likely cause behind observed renal anomalies in DYRK1A intellectual
disability syndrome patients. In addition, it shows that Dyrk1a may be acting through
the canonical Wnt pathway to exert its effects on nephrogenesis. Overall, this
dissertation reveals a new gene important for kidney development and disease
which has the potential to impact diagnostic patient treatment strategies for
DYRK1A-syndrome patients.

5.2 Future Directions
My data indicate that Dyrk1a is found in the Xenopus kidney and that Dyrk1a loss
disrupts nephrogenesis. This kidney defect can be partially rescued by adding
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Figure 24. How DYRK1A Interacts with the Wnt Pathways.
A simplified version of Figure 3 which demonstrates the downstream Wnt components that
DYRK1A, which is depicted by a green rectangle, phosphorylates of the three major Wnt
pathways. Positive regulation by DYRK1A is denoted with a green arrow while negative
regulation is denoted by a red inhibition bar. (A) DYRK1A has been shown to both positively
and negatively regulate the canonical Wnt antagonist DKK3, and negatively regulates Wnt
inhibitor GSK3β. DYRK1A has been found to positively regulate p120, which plays a
transcriptional role in the canonical Wnt pathway but also (B) regulates the small GTPases
Rac1 and RhoA, implicating it in the non-canonical PCP pathway. DYRK1A has been found
to negatively regulate ABLIM, which serves to organize the actin cytoskeleton. (C) DYRK1A
was shown to regulate the calcium pathway through several proteins. It positively regulates
RCAN1, an inhibitor of the calcium pathway and it also maintains inactive NFAT, which
likewise inhibits calcium signaling. (A-C) Lastly, DYRK1A positively regulates DVL, which is
a common component of the three major Wnt pathways.
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human DYRK1A mRNA, but patient-derived mutant mRNA has no such effect.
However, the two mutations I modeled are both kinase dead. It would be insightful to
model a patient mutation that does not result in loss of kinase function to determine
if Dyrk1a’s kinase domain is necessary for its role in kidney development. Though it
is clear that Dyrk1a knockdown results in loss of kidney tubules, I only assess this
loss by immunofluorescence and with one in situ marker. Being more thorough with
various in situ markers would be insightful such as looking at nephron sections
individually and the glomus, as well as assessing both early and late kidney
markers. In situ hybridization for early kidney markers, lim1 and hnf1β, and late
kidney marker, atp1a1, will decipher when Dyrk1a affects nephrogenesis.
Additionally, detection of different regions of kidney with late markers, slc5a1 for
proximal tubules, clckb for distal tubules, and nphs1 for the glomus is useful. This
will let me compare expression patterns to my immunofluorescence data, as the two
techniques have displayed discrepancies, especially concerning the distal and
connecting tubule presence (162). Understanding why these regions were altered
could also help pinpoint Dyrk1a’s role in kidney development.
One indirect way to assess Dyrk1a’s role would be to look at proliferation and
apoptosis in Dyrk1a knockdown kidneys, as Dyrk1a has a known role in both.
DYRK1A overexpression inhibits proliferation in neuronal progenitor cells (225), and
DYRK1A loss leads to increased proliferation in β-cells (226). This may mean
Dyrk1a loss and loss of kidney tubules in Xenopus is not due to Dyrk1a’s effect on
proliferation. In fact, DYRK1A inhibition through a compound called ID-8 was found
to stimulate human kidney epithelial cell proliferation after acute injury (227).
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DYRK1A is pro-survival through phosphorylation and activation of SIRT1, which
promotes deacetylation of p53 (228). Therefore, it could be that DYRK1A loss leads
to apoptosis ultimately loss of kidney cells and tubules.
My ambition was to implicate Dyrk1a in the Wnt pathway during kidney
development. To further understand if Dyrk1a is affecting the Wnt pathway
transcriptionally, qRT-PCR should be done with Xenopus kidneys where dyrk1a is
overexpressed. Well established Wnt target genes that are expressed in the kidney
are fgf8, lef1, wnt4, and axin2. In order to see if Dyrk1a is directly affecting the Wnt
pathway, a rescue experiment of the kidney phenotype with β-catenin would be
ideal.
A successful rescue by co-injecting non-phosphorylatable β-catenin mRNA
with the Dyrk1a MO would implicate that Dyrk1a is acting through the canonical Wnt
pathway. It is a difficult experiment because too much or too little Wnt signaling
leads to abnormal kidney development in Xenopus (43, 44) and finding the correct
dose that successfully recues will be challenging. Additionally, β-catenin perturbation
may also affect the adherens junction β-catenin pool, which may confound the
results. To get around this I could utilize the Dex inducible LefΔN-βCTA-GR755A
fusion construct, This construct consists of the DNA binding region of mouse Lef1
(HMB box amino acids 265-394), two HA tags, the C-terminal transactivation domain
(CTA) of β-catenin, and the human glucocorticoid receptor hormone-binding domain
(amino acids 512-777 with E to A substitution at 755) (44). Under normal conditions,
the glucocorticoid domain ensures the construct remains in the cytoplasm, but upon
addition of dexamethasone it translocates to the nucleus and induces Wnt target
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genes. This allows for a more precise activation of canonical Wnt signaling that may
get around some of the off target effects and difficult titration of toxic nonphosphorylatable β-catenin. An alternate approach is to alter the Wnt pathway to see
if it affects Dyrk1a levels. An obvious way to do this is by stimulating the Wnt
pathway with a Wnt ligand such as Wnt3 to see if it affects levels of DYRK1A in
kidney cell lines. Ideally this would be done in vivo, but Dyrk1a antibodies do not
work well in early Xenopus embryos. Additionally, after stimulation, CO-IP of
DYRK1A and various Wnt components such as GSK3β may illuminate where in the
pathway DYRK1A is exerting its effects. Overall, this dissertation identifies a novel
role for DYRK1A in kidney development and demonstrates that it may be acting
through the canonical Wnt pathway.
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CHAPTER 6: APPENDIX
LOSS OF P53 LEADS TO ABERRANT KIDNEY DEVELOPMENT IN XENOPUS
AND MAY LEAD TO CONGENITAL ANOMALIES OF THE KIDNEY AND
URINARY TRACT IN LI-FRAUMENI PATIENTS

6.1 Introduction
TP53, also known as p53, has long been regarded as the guardian of the
genome due to its role as a tumor suppressor and maintaining genomic stability
(231). Through this role, p53 acts as a tetramer to transcriptionally regulate genes
important for DNA repair, cell cycle arrest, and apoptosis (232). p53 has other vital
roles that are underappreciated, such as in embryonic development and
organogenesis (233). In some genetic backgrounds p53 null mice development
normally but develop spontaneous tumors by 6 months of age (234). However, in
other backgrounds mice have neural tube defects, craniofacial malformations (235)
and even congenital anomalies of the kidney and urinary tract (CAKUT) (233).
Additionally, conditional p53 deletion in mouse nephron progenitor cells leads to loss
of these progenitors and the subsequent loss of cap mesenchyme (232).
Furthermore, work in Xenopus targeting the pronephros demonstrated that dominant
negative p53 overexpression leads to complete loss of the kidney (236). Given this,
we speculated that p53 loss may similarly effect pronephric development.

6.2 Results
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6.21 P53 Knockdown or Knockout Leads to Aberrant Kidney Development in
Xenopus
Given that p53 is expressed in the Xenopus pronephros (Xenbase.org), we
sought to determine when p53 is expressed. We show by Western blot that p53 is
expressed across all stages of development including gastrulation and neurulation,
but is reduced around stage 19 during tailbud formation (Figure 25). Western blot
analysis was used to confirm that the translation-blocking antisense morpholino
(MO) correctly targets Xenopus p53 mRNA (Figure 26). Next, I sought to determine
whether loss of p53 function in Xenopus results in disruption of kidney development.
Embryos were injected in a single V2 blastomere at the 8-cell stage to target a single
kidney, leaving the other as an internal control. Knockdown with a p53 MO resulted
in abnormal pronephroi when immunostained with antibodies 3G8 and 4A6, which
label the proximal tubules and the distal and connecting tubules (nephric duct),
respectively (Figure 27). I wanted to validate these results with a second approach,
this time by knocking out the p53 gene using the CRISPR Cas9 system.
Xenopus is an allotetraploid species and has both a long and short homeolog,
or four copies of most genes, including p53. I designed two single guide RNAs
(sgRNAs) that each target both Xenopus p53 homeologs. Western blot analysis
indicates that using both guides together leads to visibly lowered p53 protein
expression at tadpole stage 37 (Figure 28A). Though, this does not mean that a
single guide does not affect p53, as Sanger sequencing indicates that the genomic
sequence of the p53 long homeolog has been edited in whole embryos using
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Figure 25. p53 Expression Across Developmental Stages.
Xenopus laevis lysates were made to assess p53 expression from blastula (3), gastrula (10),
neurula (14-19), and through tailbud (28) to tadpole (35-40) developmental stages (168).
Kidney development in Xenopus occurs from stage 12.5 to stage 40 and beyond. The blot
demonstrates that p53 expression is high in early stages and is greatly reduced in later
stages. GAPDH was used as a loading control. The bar under the molecular weight
indicates its position on the blot.
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Figure 26. The p53 Morpholino Correctly Targets p53 mRNA in Xenopus.
Western blot analysis demonstrates that p53 protein levels are reduced in blastula embryos
(stage 10-12) upon morpholino knockdown indicating that the MO correctly targets p53
mRNA. Embryos were injected with 40 ng of p53 MO or standard (Std) MO. GAPDH is used
as a loading control. The bar under the molecular weight indicates its position on the blot.
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Figure 27. p53 Knockdown Leads to Loss of Kidney Tubules in Xenopus.
Embryos were unilaterally injected at the 8-cell stage with 20 ng of p53
MO or standard MO. Stage 40 tadpoles were immunostained with kidney antibodies 3G8,
which labels the proximal tubules, and 4A6, which labels the distal and connecting tubules.
Letters without apostrophes (A–B) represent the injected side, whereas letters with
apostrophes (A’–B’) represent the uninjected side. (A) The Standard MO has no affect while
(B) knockdown with a translation-blocking p53 MO disrupts kidney development.
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Figure 28. p53 Can be Knocked Out with CRISPR/Cas9 Technology in Xenopus.
(A). Western blot analysis of stage 37-40 tadpole lysates demonstrates that injecting single
cell embryos with both sgRNA 1 and 2 (p53.1 and p53.2) leads to lowered p53 expression
as seen with a p53 antibody. SLC serves as the negative control while GAPDH serves as
the loading control. Uninj = uninjected. The bar under the molecular weight indicates its
position on the blot. (B) To verify that p53 knockout was obtained, I injected single-cell
embryos and then sequenced individual embryos around the region where the Cas9 protein
targets for cutting. The chromatogram of the p53 CRISPR embryo demonstrates that the
sequence before the cut site appears normal, whereas after the cut site, the sequence
appears to degrade and a good read was not ascertained. The chromatogram of the wildtype embryo has no degradation of its peaks. (C) TIDE analysis shows that most embryos
that had Cas9 cutting lead to a four base pair deletion, most likely leading to a nonfunctional protein. (D) A majority of all cutting (75%) lead to out of frame deletions, followed
by out of frame insertions (7%) and in frame deletions (2%). Only 16% of embryos had no
editing.
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sgRNA 1 alone (Figure 28B). To gain a more thorough understanding of the
CRISPR edits I used TIDE analysis, which compares wild-type embryos to
CRISPRed embryos and establishes the efficacy of cutting as well as the most likely
types of indels that specific guide has caused. TIDE analysis showed an almost 70%
cutting efficiency with 75% of cuts being out of frame deletions, a majority of which
result in a 4 base pair deletion, likely leading to a non-functional p53 protein (Figure
28B).
After this validation, I injected sgRNA 1 into 8 cell embryos targeted to a
single kidney. I found that the p53 CRISPR/Cas9 method phenocopied the p53 MO
and lead to loss of kidney tubules (Figure 29). Because I was able to get a kidney
phenotype and degraded sequence, it is likely that there is reduced p53 expression,
it is just not visible by Western blot. Given that the kidney loss result could be
replicated with two different methods of p53 loss, it suggests that p53 is responsible
for the kidney phenotype, rather than off-target effects of either approach.

6.22 Dominant Negative RNA From Li-Fraumeni Patients Leads to Abnormal
Kidney Development in Xenopus
Next, we sought to establish if the p53 kidney phenotype had human
relevance. Mutations in TP53 at a single allele in humans results in a dominant
negative disease known as Li Fraumeni syndrome. These patients have a
predisposition for developing various types of cancers that are early onset.
Interestingly, it was found through unpublished MRI data that a cohort of Li Fraumeni
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Figure 29 p53 Knock Out Leads to Loss of Kidney Tubules in Xenopus.
Embryos were unilaterally injected at the 8-cell stage with 500 ng of p53
sgRNA and 1 ug of Cas9 protein along with a RFP tracer. Stage 40 tadpoles were
immunostained with kidney antibodies 3G8 and 4A6. (A) The uninjected side has a normal
pronephros while (B) the injected side knocks out p53 and disrupts kidney development.
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patients has a higher prevalence of CAKUT (31% compared to 10% in control group)
including kidney hypoplasia, renal cysts or benign kidney tumors, or agenesis,
ovarian cysts, or uterine agenesis. Of the 29 Li-Fraumeni patients examined, 45%
had glomerular filtration rates lower than 90, which is a clinical readout of kidney
function and under 90 demonstrates impairment. These mutations can result in
functional loss of p53, but also can result in dominant negative function in patients.
Because p53 acts as a tetramer to bind DNA, mutant p53 can form tetramers with
wild-type p53, resulting in inhibition of wild-type p53 function (237).
We chose to model two different human mutations in Xenopus that are
thought to have a dominant negative effect as it has been shown that
overexpressing a dominant negative form of p53 leads to loss of kidney tubules in
Xenopus (236). The first mutation, p53 R248W, is found in the DNA binding domain of
p53 and has been previously characterized in Xenopus (236). It is also known to
disrupt DNA binding by eliminating essential minor groove contacts (238). A patient
with this mutation in this cohort was found to have a simple kidney cyst 6.8 cm in
diameter. The second, p53 R282W, is novel and is also found in p53’s DNA binding
domain and is speculated to also have dominant negative function. The patient
suffers from a complex kidney cyst 3.4 cm in diameter and kidney lesions.
We used site-directed mutagenesis to obtain both mutations and synthesized
mRNA, along with human wild-type p53. The constructs all contain two flag epitopes.
Western blot analysis with both p53 and flag antibodies was used to confirm that the
wild-type human p53, p53R248W, and p53R282W mRNA are successfully expressed in
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Xenopus embryos (Figure 30). From Western blot analysis, it appears that the
p53R282W mutation has lower levels of expression than wild-type or p53R248W. This is
likely due to protein stability, as the mutation may interfere with maintaining the
correct protein conformation. We than injected either wild-type p53, p53R248W, or
p53R282W mRNA into the V2 blastomere of 8-cell embryos to target a single kidney to
find a subphenotypic dose of wild-type p53, as too much p53 has been shown to
cause abnormal kidney development (239). We found that 300 pg elicits a moderate
loss of kidney tubules with either p53R248W or p53R282W, but not with wild-type p53
that is statistically significant (Figure 31).

6.3 Discussion
p53 is perhaps the most well-known tumor suppressor, but it has other
important roles in both embryogenesis and organogenesis (233). Conditional p53
deletion in mouse nephron progenitor cells leads to loss of cap mesenchyme, which
is where nephrons arise from (232). Previous work in Xenopus has even shown that
dominant negative p53 overexpression alters kidney development (236). Given that
loss of p53 by two independent methods or overexpression of dominant negative
p53 which can inhibit wild-type p53 leads to kidney abnormalities, it likely plays a
role in nephrogenesis.
Here, we report that p53 affects Xenopus nephrogenesis: loss of p53 with
either MO (Figure 27) or CRISPR/Cas9 (Figure 29) strategies led to loss of kidney
tubule formation. Both methodologies were verified with Western blot analysis and/or
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Figure 30. Human p53 Wild-type and Mutant Proteins are Expressed in Neurula Stage
Xenopus Embryos.
Single-cell embryos were injected with 1 ng of either wild-type, R248W, or R282W human
p53 mRNA along with a membrane RFP tracer. Western blot analysis demonstrates that
human wild-type and mutant p53 mRNA can be successfully translated in Xenopus
embryos. Of note, the R282W mutant has lower expression than either the wild-type or other
mutant p53. This may represent that this mutant protein is less stable than the R248W
mutant. β-gal serves as a negative control. The two point (C742T, p53 R248W and C844T, p53
R282W)

mutant constructs were generated with site-directed mutagenesis from a wild-type

human pCdna3-Flag-p53 vector. GAPDH was used as a loading control. The bar under the
molecular weight indicates its position on the blot. Western blot was performed by
undergraduate Amisheila Kinua and is used here with her permission.
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Figure 31. Mutant Human p53 Disrupts Kidney Development in Xenopus.
(A–D) Embryos were unilaterally injected at the 8-cell stage with 300 pg of
β-gal, wild-type, p53R248W, or p53R282W mRNA. Stage 40 tadpoles were stained with kidney
antibodies 3G8, which labels the proximal tubules, and 4A6, which labels the distal and
connecting tubules. Letters without apostrophes (A–D) represent the injected side, whereas
letters with apostrophes (A’–D’) represent the uninjected side. (C-D) Overexpression of
mutant p53 disrupts kidney development while (B) wild-type p53 does not. (A) β-gal serves
as a negative control and scale bars represent 100 μm. (E) The graph demonstrates a
significant difference between embryos injected with either p53R248W, or p53R282W mRNA
compared to those injected with wild-type p53 mRNA. Significance was established against
embryos that had a weak (yellow bar), moderate (orange bar) or severe kidney (red bar)
phenotype using a two tailed T-test. Double asterisk (**) indicates p < 0.007 while triple
asterisk (***) indicates p < 0.0006. Error bars represent standard error. For scoring system
of Xenopus embryonic kidneys, please refer to Figure 14.
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Sanger sequencing/TIDE analysis. Because p53 has an essential role in apoptosis,
future research should include both proliferation and apoptosis assays to assess if
either accounts for the kidney phenotype found in these embryos.
Furthermore, we present a novel genetic contribution of p53 to CAKUT in
patients with Li-Fraumeni syndrome. Our collaborator Zubaida Saifudeen identified
from clinical MRIs that nine of twenty-nine (31%) Li-Fraumeni patients in this study
with both non-functional and dominant negative mutations have a higher prevalence
of CAKUT. Additionally, thirteen of the twenty-nine (45%) Li-Fraumeni patients
examined had glomerular filtration rates lower than 90, which indicates loss of
kidney function.
We found that overexpression of Li-Fraumeni patient mutant mRNA led to a
similar phenotype as loss of p53, though the kidney defect was less severe. This
indicates that dominant negative variants in this gene are likely causative for the
observed CAKUT phenotype in some patients. The human mutant mRNA may elicit
a more attenuated phenotype because it may not exert a dominant negative affect to
every DNA binding tetramer it forms or not all p53 tetramers acquire mutant
monomers. Western blot also demonstrates mutant p53 is potentially less stable,
thus a portion of it could degrade before kidney development is finished ultimately
leading to a lessened effect. In summary, p53 plays a role in both Xenopus and
human kidney development. Based on our data, we empirically recommend that
individuals with Li-Fraumeni syndrome undergo a renal and urogenital ultrasound as
part of their clinical workup.
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